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Summary 
 
Viruses and their hosts co-evolve and both sides constantly adapt to develop more refined 
methods to gain the upper hand in this arms race. In an infected cell viral components 
activate the innate immune system of the cell, which leads to the production of interferons. 
This in turn triggers the expression of numerous antiviral proteins in the infected as well as 
neighboring cells. We focused on one group of those interferon-induced proteins: the Mx 
proteins. These are dynamin-like GTPases, which exert antiviral activities against a wide 
range of viruses. Different Mx proteins localize to different subcellular compartments and 
also vary in their antiviral specificity. Human MxA has been studied extensively in its antiviral 
function against many negative-stranded RNA viruses, among them influenza A virus (IAV). 
However, despite intense efforts the antiviral mechanism is still not resolved yet. Human IAV 
strains seem to have adapted to MxA, since they are generally more resistant to MxA as 
opposed to avian IAV strains. It is clear that the nucleoprotein (NP) of IAV represents the 
target of MxA, not only because it shows binding to MxA but also because a small number of 
mutations in NP alter the sensitivity of those virus strains to MxA dramatically. The closely 
related human MxB protein, on the other hand, has only recently been associated with 
antiviral functions and has been shown to inhibit lentiviruses and herpesviruses. 
In this thesis we investigated the potential of MxB to inhibit IAV. We showed that by artificially 
changing the localization of MxB to the nucleus, MxB potently inhibits IAV primary 
transcription like MxA, which is re-localized to the nucleus and the mouse homolog Mx1, 
which naturally resides in the nucleus. The finding, that nuclear MxB harbors the potential to 
restrict IAV suggests the existence of a universal antiviral mechanism of Mx proteins. We 
further aimed at gaining a more insights into the molecular processes of IAV restriction by 
MxA. MxA and viral NP both associate with UAP56, a cellular RNA helicase involved in 
mRNA nuclear export. It also acts as a chaperone on newly synthesized viral NP to deliver it 
safely to viral RNA in the nucleus. We showed that MxA does not inhibit the shuttling of 
newly translated NP, chaperoned by UAP56, from the cytoplasm to the nucleus. Also, the 
sensitivity of different IAV strains to MxA does not positively correlate with the capacity of 
NPs of those viral strains to bind to MxA. Stable binding of MxA to NP is only observed with 
dimeric MxA mutants and independent of its activity. We further showed that two residues in 
NP, which are associated with NP oligomerization, are crucial for its binding to MxA and 
UAP56, since binding to both proteins is abrogated when those two residues are mutated. 
We thus suggest that MxA induces post-translational modifications on NP and/or UAP56 by 
recruitment of additional factors, which abrogates the functional integrity of the NP-UAP56 
complex. 
 v 
 
Zusammenfassung 
 
Viren und ihre Wirtsorganismen passen sich laufend einander an. Das Virus entwickelt 
Strategien um das Immunsystem der Zelle zu umgehen und die Zelle wiederum entwickelt 
immer komplexere Systeme für eine erfolgreiche Bekämpfung von Pathogenen. Virale 
Moleküle werden in einer infizierten Zelle von speziellen Rezeptoren des angeborenen 
Immunsystems erkannt und als Reaktion darauf werden Proteine, sogenannte Interferone, 
produziert. Diese Interferone induzieren die Expression zahlreicher antiviraler Proteine 
sowohl in der infizierten Zelle, als auch in den Nachbarzellen. In dieser Dissertation 
fokussierten wir uns auf eine Familie solcher antiviraler Proteine, die sogenannten Mx 
Proteine. Diese Dynamin-ähnlichen GTPasen weisen eine hohe antivirale Aktivität gegen 
eine Vielzahl unterschiedlicher Viren auf, unterscheiden sich jedoch in ihrer antiviralen 
Spezifität und ihrer subzellulären Lokalisation. Humanes MxA Protein inhibiert DNA- und 
RNA-Viren, primär jedoch letztere, zu denen unter anderem Influenzaviren gehören. Trotz 
großer Bemühungen konnte der antivirale Mechanismus von MxA bis heute noch nicht gelöst 
werden. Es wurde jedoch gezeigt, dass sich die humanen influenza A virus (IAV) Stämme 
besser an MxA adaptiert haben als die aviären Stämme, welche generell sensitiver gegen 
die antivirale Aktivität von MxA sind. Zudem wurde gezeigt, dass das Angriffsziel von MxA 
das virale Nukleoprotein (NP) ist, da MxA und NP zum einen interagieren und zum anderen 
nur wenige Mutationen im NP die Sensitivität für MxA dramatisch verändern.  
Dem eng verwandten humanen MxB Protein sind im Gegensatz zu MxA erst kürzlich 
antivirale Funktionen zugeschrieben worden. Es wurde gezeigt, dass MxB die Replikation 
von Lentiviren und Herpesviren inhibiert. 
In dieser Dissertation haben wir MxB zu dessen Potential untersucht IAV zu hemmen. Wir 
konnten zeigen, dass MxB, welches artifiziell in den Zellkern verschoben wurde (TMxB), die 
Primärtranskription von IAV stark inhibiert. Dieser Mechanismus scheint der gleiche zu sein 
wie der von Mx1, dem MxA Homolog in Mäusen, welches sich im Kern befindet, und von 
nukleärem MxA, welches artifiziell in den Zellkern verschoben wurde. TMxB bindet zudem an 
NP, was auch für MxA und MxB gezeigt wurde. Diese Befunde deuten auf einen universellen 
antiviralen Mechanismus von Mx Proteinen hin. 
Das Ziel dieser Arbeit war einen tieferen Einblick in die molekularen Prozesse der IAV 
Restriktion durch MxA zu gewinnen. MxA und das virale NP assoziieren mit UAP56, einer 
zellulären RNA Helikase, welche in den mRNA Transport involviert ist. Darüber hinaus spielt 
UAP56 eine wichtige Rolle im Zusammenhang mit IAV, da es als Chaperon fungiert um 
frisch synthetisiertes NP sicher zur viralen RNA im Zellkern zu transportieren. Wir zeigten, 
dass MxA den Transport des UAP56-NP Komplexes in den Kern nicht beeinflusst. Des 
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Weiteren konnten wir beobachten, dass die Sensitivität von verschiedenen IAV Stämmen für 
MxA nicht positiv mit der MxA-Bindungskapazität der NPs dieser Stämme korreliert. Eine 
stabile Bindung zwischen MxA und NP konnten wir mit der dimerischen Form von MxA 
sehen und diese Bindung ist interessanterweise unabhängig von der Aktivität von MxA. Wir 
konnten zudem zeigen, dass zwei bestimmte Aminosäurereste im NP, welche mit dessen 
Oligomerisierung assoziiert sind, für die Aufrechterhaltung des Bindungspotentials zu MxA 
und UAP56 entscheidend sind. Diese Bindung wurde zerstört, wenn diese zwei Aminosäuren 
zu Alanin mutiert wurden. Wir schlagen deshalb vor, dass MxA mit der Hilfe zusätzlicher 
Faktoren posttranslationale Modifikationen in NP und/oder UAP56 hinzufügt. Diese 
Modifikationen wiederum setzen die Funktion des NP-UAP56 Komplexes außer Kraft.  
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1 Background 
 
1.1 Influenza A virus 
 
Influenza A viruses (IAVs) are the causing agents of the illness commonly known as the flu. 
For a healthy individual an IAV infection is generally non-fatal and cleared after 7 to 10 days. 
Phenotypic manifestations include fever, muscle and joint pain, fatigue and milder symptoms 
such as a runny nose or a headache. Nevertheless, IAV infection is particularly dangerous to 
children, elderly people and immunocompromised individuals and an infection can lead to the 
death of those patients. IAV infections are especially evident in the annual flu epidemics and 
thus pose a recurrent health threat. These epidemics result in high economic losses (3 to 5 
million cases of severe illness) as well as many deaths (290’000 - 650’000) (WHO, February 
2018). There have also been a number of pandemics, worldwide Influenza outbreaks, first 
and foremost the so-called Spanish flu in 1918-20, infecting over 500 million people and 50-
100 million deaths (3-5% of the world’s population)1. Besides humans, IAV also infects other 
mammals as well as birds, where aquatic birds represent the natural reservoir2. 
IAV normally infects epithelial cells of the upper and lower respiratory tracts in humans with 
virus predominantly replicating in the upper airways and trachea. In fatal cases high virus 
loads can also be found in the lower respiratory tract3. In birds, on the other hand, the 
primary site of IAV replication is the gastrointestinal tract4. Independent of IAVs host tropism 
it binds to the same receptor, which is sialic acid on glycosylated host cell proteins. 
IAV is a rapidly mutating virus, which enables fast evasion from the host antibody response, 
a phenomenon also called antigenic drift5, leading to the occurrence of seasonal influenza 
epidemics. The rapid generation of virions harboring adaptive mutations is also the reason 
for the need to annually produce new vaccines. Antigenic shift on the other hand is a 
process, where a virus of a new subtype is introduced into the human population potentially 
leading to pandemic outbreaks. This antigenic change can occur through reassortment, 
which is the swapping of gene segments between at least two different viruses6. Antigenic 
shift, however, occurs much less frequently than antigenic drift. Since the early 20th century 
four IAV pandemics have occurred: the ‘Spanish flu’ (H1N1) in 1918, the Asian pandemic 
(H2N2) in 1957, the Hong Kong pandemic (H3N2) in 1968 and the ‘swine flu’ (H1N1) in 
20097. Nevertheless, infections with viruses originating in various animal species are 
generally not transmitted from human to human and the pandemic potential is thus relatively 
low7.  
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1.1.1 IAV virion structure 
 
IAV belongs to the orthomyxovirus family and is an enveloped, single-stranded RNA virus 
with a segmented genome of negative polarity2,8. Typically, virions are spherical particles of 
approximately 100 nm in diameter but also rod-shaped up to 300 nm long virions are 
observed. The viral genome is segmented and consists of 8 strands, each associated with 
numerous copies of the nucleoprotein (NP) and one single RNA-dependent RNA polymerase 
(RdRp) complex composed of the three proteins polymerase basic protein 1 (PB1), 
polymerase basic protein 2 (PB2) and polymerase acidic protein (PA). The resulting so-
called viral ribonucleoprotein complexes (vRNPs) are bound through NP to the matrix protein 
M1. The virus displays two glycoproteins on its surface; hemagglutinin (HA), important for 
binding to the influenza receptor sialic acid on the host cell surface, and neuraminidase (NA), 
responsible for the release of the virions after budding by hydrolyzing glycosylic linkages on 
cell surface glycoproteins. These two types of viral glycoproteins are embedded in the viral 
envelope, a lipid bilayer derived from the host cell plasma membrane. 
 
 
 
Fig. 1.1. Structure of influenza A virus. The 8 genomic viral RNA (vRNA) segments are 
encapsidated in numerous copies of the nucleoprotein (NP). Each segment is further associated with 
one polymerase complex comprising the proteins polymerase basic protein 1 and 2 (PB1 and PB2) 
and polymerase acidic protein (PA). vRNA plus NP and the polymerase is called a viral 
ribonucleoprotein (vRNP) complex. These complexes are associated with the matrix protein 1 (M1), 
which is situated right underneath the viral host-derived envelope. The envelope is studded with the 
Haemagluttinin (HA)
Neuraminidase (NA)
Matrix protein 1 (M1)
PB1, PB2 and PA
Nucleoprotein (NP)
M2 ion channel
viral RNA
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two viral surface glycoproteins hemagglutinin (HA) and neuraminidase (NA). The M2 ion channel also 
resides in the viral envelope. 
 
There are 16 different HA and 9 different NA protein subtypes, classified according to their 
sequence similarities. This is also how the names of different IAV strains are derived from. 
The H and N in a given virus strain (eg. H5N1) stand for the subtypes of HA and NA proteins 
(HA protein of subtype 5 and NA protein of subtype 1 in this example). Two other influenza-
like viruses have recently been discovered in bats: H17N10 and H18N119,10. They are 
classified as ‘influenza-like’ viruses, since the HA and NA proteins have some unusual 
features unseen in influenza A viruses. These include the missing sialidase function of the 
NA protein and the inability of HA to bind to sialic acid.  
Additionally to the two surface glycoproteins, an ion channel (M2) is located in the viral 
envelope8. The eight viral genome segments encode for 14 proteins in total11,12, each 
segment encodes at least one protein. Besides PB2, PB1, PA, HA, NP, NA, M1 and M2 
these segments further encode for several non-structural proteins: NS1, NS2/NEP, PB1-F2, 
PB1-N40, PB2-S113, PA-X, PA-N15512, PA-N18212 and M4211. NS1 is a multifunctional 
protein with a major role in antagonizing the host innate immune response14. It does so by 
interacting with and inhibiting retinoic-acid inducible gene 1 (RIG-I) downstream signaling but 
also shielding viral dsRNA from recognition by its receptor. NS1 also inhibits cellular pre-
mRNA maturation and nuclear export15,16 and it is involved in viral mRNA translation 
regulation17. On the same segment as NS1 the nuclear export protein NEP (also known as 
NS2) is encoded, which plays a crucial role as vRNP exporter into the cytoplasm after vRNP 
assembly18. PB1-F2 is associated with initiation of apoptosis, increasing sensitivity to 
secondary bacterial infections and the regulation of polymerase activity19. The functions of 
PB1-N40, PB2-S1, PA-X, PA-N155, PA-N182 and M42 are less thoroughly investigated. It is 
thought that PB1-N40, an N-terminally truncated PB1 version, regulates transcription and 
replication20. PB2-S1 is translated from an alternative splice variant of the PB2 mRNA. 
Functionally it has been shown that it can inhibit RIG-I-dependent interferon signaling as well 
as viral polymerase activity but its relevance for viral replication and pathogenicity is 
questionable13. PA-X harbors the same N-terminus as PA but its C-terminus is truncated and 
different in sequence as a result of ribosomal frameshifting21. It was shown to induce the 
degradation of host mRNAs and its loss leads to increased inflammation, apoptosis and 
induction of the adaptive immune system22,23. PA-N155 and PA-N182 are translated from 
alternative AUG codons from the PA mRNA at the 11th or 13th in-frame position after the PA 
start codon12. A specific function has not been assigned to those two proteins yet. It has 
been shown, however, that they do not harbor polymerase function in combination with PB1 
Background 
4 
 
and PB2. M42, a splice variant of M2, has been proposed to also have an ion-channel 
function similar to M2 and to be able to replace the function of M2 in vitro and in vivo11.  
 
1.1.2 IAV replication cycle 
 
One of the first hurdles a virus needs to overcome is the entry into the host cell. IAV 
initializes this entry process by binding to the host cell surface via its receptor sialic acid. 
Depending on how these sialic acid residues are linked to other sugar moieties, they are 
more strongly bound by human or bird influenza viruses. Human viruses preferentially bind to 
α2,6-linked sialic acids, which are found in the upper respiratory tract, whereas bird influenza 
viruses favor α2,3-linkages24,25 present on intestinal epithelial cells26. The virus subsequently 
gets internalized mainly via clathrin-mediated endocytosis and travels along the endocytic 
route to late endosomes27. The drop in pH leads to the ion channel M2 pumping protons into 
the virion and the lower pH triggers the release of the vRNPs from the matrix protein M1. 
Following the cleavage of the HA precursor protein HA0 to HA1 and HA2 by cellular 
proteases, which exposes IAVs fusion peptide, acidification in the late endosomes further 
leads to a conformational change in HA and subsequently fusion of the viral with the cellular 
endosomal membrane28. The vRNPs are imported into the nucleus, where primary 
transcription takes place and viral mRNA transcripts are generated through a cap-snatching 
mechanism. Thereby the virus cleaves of the 5’-cap on cellular mRNAs and uses them for 
the production of viral mRNA molecules, thus disguising its own transcribed RNAs as cellular 
mRNAs. These viral RNA transcripts are exported into the cytoplasm and translation by the 
host cell machinery is initiated. Newly synthesized NP as well as the viral polymerase 
translocate to the nucleus, where they drive viral genome replication. NP thereby binds co-
replicationally to the nascent viral genomes29. NA and HA proteins, which are translated at 
the endoplasmic reticulum (ER), travel to the plasma membrane via the trans-Golgi network 
(TGN), where they are associated with lipid raft domains30. 
Newly assembled vRNPs exit the nucleus and are transported to the plasma membrane 
most likely via Rab11-positive endosomes31. Influenza virions assemble and bud from the 
plasma membrane and NA subsequently cleaves sialic acid to release the virions from the 
host cell. 
There are basically two steps, at which IAV can be currently inhibited by antiviral drugs. 
Firstly, the acidification of endosomes can be inhibited by targeting the ion channel M2 so 
that the virus is unable to perform uncoating and the vRNPs cannot be released into the 
cytoplasm. These drugs are called adamantane (eg. Amantadine, Rimantadine). The other 
group of drugs inhibits the sialidase function of NA so that the progeny virus is not released 
from the plasma membrane. Zanamivir and Oseltamivir (commonly known as Tamiflu) 
Background 
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belong to this category of neuraminidase inhibitors32. Due to the IAVs high mutation rate and 
the high selection pressure for drug evasion many circulating virus strains are already 
resistant to both classes of anti-IAV drugs33, thus, there is urgent need to develop new 
antivirals or a universal vaccine. 
IAV binding, 
endocytosis, 
fusion
cRNA
synthesis
primary
transcription
trafficking
Nucleus
vRNP nuclear import
Replication
virion 
assembly, 
budding
Translation
vRNP
assembly
 
Fig. 1.2. IAV replication cycle. Upon binding of IAV to its receptor sialic acid the virions get 
internalized via clathrin-mediated endocytosis and travel through the endosomal pathway. Acidification 
of the endosomes and with the help of the M2 ion channel also of the viral core induces structural 
changes in HA, which enable the viral envelope and the host endosomal membrane to fuse. After 
fusion the vRNPs are imported into the nucleus, mRNA transcription is initiated and mRNA is exported 
to the cytoplasm. After host-dependent translation the viral polymerase complex and the nucleoprotein 
travel back to the nucleus where they assist in viral genome replication. vRNPs are assembled in the 
nucleus and reach the plasma membrane through endosomal trafficking. Virions are assembled at the 
plasma membrane and released by NA activity. HA: hemagglutinin, vRNP: viral ribonucleoprotein 
complex, NA: neuraminidase  
 
1.1.3 A closer look on the nucleoprotein NP of IAV 
 
NP is a key viral protein, involved in many processes during the viral replication cycle. NP is 
the major component of vRNPs and an RNA-binding binding protein. Its affinity to bind to 
RNA is high but unspecific, meaning not selective for viral RNA34,35. NP also interacts with 
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two other components of the vRNP: PB1 and PB2, two of the three subunits of the viral 
polymerase36,37. NP enables the vRNPs to reach the nucleus via its nuclear localization 
signals (NLS)38. Those NLS motifs associate with importin-α and are subsequently 
transported through the nuclear pore39. NP stabilizes viral RNA by concomitant 
encapsidation during cRNA synthesis and vRNA production40. This encapsidation is initiated 
by binding of an NP monomer to the RNA-bound polymerase. Subsequent addition of NP 
molecules during RNA elongation is achieved through NP-NP binding and homo-
oligomerization41-43. Intriguingly, it has also been suggested that vRNP CRM1-dependent 
export prior to virion assembly is mediated by NP44. NP is further required for packaging of 
some RNA segments45. The various functions of NP are regulated via post-translational 
modifications such as phosphorylation (prevents premature NP oligomerization41,46), 
SUMOylation (important for intracellular trafficking of NP47), ubiquitination (affecting its 
binding affinity to nascent cRNA48) and acetylation (affecting polymerase activity and virion 
release 49). 
NP has been shown in vitro to form homo-oligomers: trimers50-52, tetramers51 and even higher 
oligomers50. The oligomerization capacity of NP is dispensable for initiation and termination 
of viral genome replication, however, it is crucial for the elongation and assembly of the 
nascent vRNA52-54. It has further been suggested, that NP needs to be kept in the monomeric 
state previous to binding to and polymerizing on the vRNA29,55,56. This function is exerted by 
the cellular chaperone UAP5629,57 and possibly also by its close relative URH4957. 
NP is highly conserved between different strains of IAV, nevertheless, some structural 
differences are obvious. So far, H1N1 and H5N1 NP have been crystallized50,51, which 
resulted in trimers. They harbor a C-terminal tail loop, important for the formation of 
oligomers and an insertion groove, the binding site for the tail loop (Fig. 1.3). The positively 
charged RNA-binding groove is located opposite of the insertion groove. When comparing 
H5N1 (Fig. 1.3A) and H1N1 (Fig. 1.3B) NP, it is obvious that the angle at which the tail loop 
is protruding from the body of the protein is different. Even though the trimeric structure of 
H5N1 and H1N1 (Fig. 1.3C) NPs therefore differ considerably, the interaction of the tail loops 
with the insertion grooves are virtually the same51 (Fig. 1.3D). NP can be rendered 
monomeric via point mutations: R416A (in the tail loop), E339A (in the insertion groove) and 
S165D (in the insertion groove, phosphomimetic) (shown in yellow in fig. 1.3 A and B). 
Introducing the R416A mutation, the positive charge of the RNA-binding groove is reduced 
concomitantly55. In contrast to R416A and E339A, IAV harboring NP(S165D) can be grown, 
although strongly attenuated, which indicates that this substitution does not render NP 
exclusively monomeric46,58. 
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Fig. 1.3. Structure of H5N1 and H1N1 nucleoprotein. Crystal structure of a single NP protomer. 
Residues, which were shown to influence the oligomeric state of NP are marked in yellow. A) H5N1 
NP crystal structure (RCSB ID: 2q06, A/HK/483/97) of one protomer adapted from 51. B) H1N1 crystal 
structure (RCSB ID: 2iqh, A/WSN/1933) of one protomer from 50. C) Trimeric H1N1 NP as in B). Single 
NP molecules are shown in different colors. D) Comparison of H5N1 (left) and H1N1 (right) 
interactions domains (adapted from 51). The stalk of one NP monomer (red or blue, respectively) 
F412 
R416 
E339 
S165 
F412 
S165 
45° 
F412 
R416 
F412 
R416 
E339 
S165 
top view in 
direction of arrow 
45° 
A 
C 
B 
D 
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inserts into the insertion groove of another NP molecule (light blue or rose, respectively). The 
structures of the trimeric interaction domains are virtually identical. 
 
1.2 Innate immune system 
 
 
The cell has evolved two main systems to defend against pathogens: the fast and broadly 
acting innate immune system and the slow but more specialized adaptive immune system. 
The first line of defense of a cell against an incoming virus is the interferon system59 (Fig. 3), 
a part of the innate immunity. Viral proteins or nucleic acids, harboring so-called pathogen-
associated molecular patterns (PAMPs) thereby bind to pattern recognition receptors 
(PRRs). These are either Toll like receptors (TLRs) in endosomes or RIG-I like receptors 
(RLRs) in the cytoplasm60-62. For IAV, TLR 3 and TLR7, which recognize viral dsRNA and 
ssRNA in endosomes, respectively, and RIG-I, sensing viral 5’ triphosphate RNA63,64, are of 
particular importance. The binding to their target molecules activates the downstream 
effectors, eventually leading to the activation and nuclear translocation of interferon 
regulatory factors 3 and 7 (IRF3 and IRF7). These transcription factors subsequently activate 
the expression of interferons of the type I and III (interferon (IFN) α, β and λ), their levels 
depending on the cell type65. Secreted IFNs then bind in an auto- and paracrine manner to 
their cognate receptor, interferon-α or -λ receptor (IFNAR or IFNLR). Receptor subunit 
dimerization activates Janus Kinase (JAK) family tyrosine-protein kinases Janus Kinase 1 
(Jak1) and Tyrosine Kinase 2 (TYK2). These two kinases phosphorylate the receptor tail, 
forming a binding site for Signal Transducers and Activators of Transcription 1 and 2 (STAT1 
and STAT2) proteins66. Bound STATs in turn get phosphorylated by JAKs and form 
heterodimers. These dimers associate with IFN regulatory factor 9 (IRF9) and translocate to 
the nucleus59, where they activate transcription of over 300 interferon-stimulated genes 
(ISGs), many of them with intrinsic antiviral activity. There are many well-characterized ISGs 
in the battle against IAV and the three most prominent examples are protein kinase R (PKR), 
2’-5’ oligoadenylate-synthetase (OAS) and IFN-induced transmembrane (IFITM) protein 
family members. PKR is a Ser/Thr protein kinase, which is activated by double-stranded 
RNA (dsRNA)67,68. Activation of PKR leads to auto-phosphorylation, which further results in 
phosphorylation of downstream target proteins69. One of those target proteins is the 
translation initiation factor eIF2. Phosphorylated eIF2 is inactive, thus translation of cellular 
and viral mRNAs is blocked70 and hence the virus is unable to perform genome replication. 
OAS is also stimulated by dsRNA, inducing the production of 2’-5’ oligoadenylic acid from 
ATP71,72. These ATP species in turn activate RNase L, which cleaves viral and cellular 
single-stranded RNA (ssRNA)73. Activation of RNase L additionally stimulates autophagy74 
and apoptosis75 further enhancing the antiviral effect. IFITM3, the major anti-IAV protein of 
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the IFITM protein family inhibits IAV even before the virus undergoes uncoating and entry 
into the host cell due to its transmembrane nature76-78. The mechanism is poorly defined so 
far79, but for HIV it has been shown, that IFITMs get incorporated into the viral membrane 
and decrease virus infectivity80,81. It has also been shown that IFITMs specifically target the 
viral envelope protein (Env) during assembly impairing the incorporation of Env into the 
virions82. The human myxovirus resistance protein 1 (MxA) is another well-known ISG, which 
plays an important role in the struggle against many different viruses including IAV59. A 
detailed description can be found in chapter 1.3. 
Since the innate immune system is a very potent and fast acting antiviral mechanism, IAV 
has also evolved means to counteract it. The multifunctional NS1 protein plays a major role 
thereby. It can bind directly to RIG-I and thus inhibit the downstream activation of IRF3 and 
eventually IFN production83-86. NS1 can also indirectly inhibit RIG-I activation by binding to 
dsRNA and thereby shielding it from the recognition by cellular sensors85-88. Recently it has 
been shown that the virus carries RIG-I antagonizing factors in the virions: the polymerase 
subunits PB1 and PA suppress IFN induction possibly through direct interaction with RIG-I89. 
NS1 also is capable of blocking the function of OAS and PKR by out-competing those two 
proteins for dsRNA binding90,91 or even through direct interaction with PKR14,69,91. 
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Fig. 1.3. IFN induction and the JAK/STAT pathway. A) Stimulation of PRRs TLR3 and 7 and RIG-I 
leads to the activation of downstream effectors IRF3 and 7. Binding of those transcription factors to an 
ISRE activates transcription of the IFN gene. IFN protein is secreted and auto- and paracrine signaling 
is activated. B) IFN produced as in A) binds to its receptor subunit 2 (IFNAR2) and triggers 
dimerization of subunit 1 and 2. The following activation of Jak and Tyk leads to the phosphorylation 
and activation of STAT1 and STAT2. STAT1 and STAT2 form heterodimer, associate with IRF9, 
translocate to the nucleus and activate the transcription of various ISGs. PRR: pattern recognition 
A 
B 
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receptor, TLR: toll-like receptor, RIG-I: retinoic-inducible gene 1, TRIF: TIR-domain-containing 
adapter-inducing interferon-β, MyD88: myeloid differentiation primary response 88, IRF: interferon 
regulatory factor, MAVS: mitochondrial antiviral-signaling protein, IFN: interferon, ISRE: interferon-
stimulated response element, JAK: Janus kinase, STAT: signal transducers and activators of 
transcription, Tyk: tyrosine kinase, IFNAR/IFNGR: interferon alpha/gamma receptor 
 
1.3 Mx proteins 
 
In 1962, a protein called myxovirus resistance protein 1 or Mx1 (myxovirus is an outdated 
term to describe viruses, which infect the respiratory tract) was discovered in inbred mouse 
strains92. This interferon-inducible protein protected mice very potently against lethal doses 
of IAV. Two years later the coding region for this protein was mapped to a single gene, Mx1, 
on chromosome 1693. In humans the Mx1 locus on chromosome 21 codes for a protein 
named MxA, which shares some, but not all features of Mx1. Another gene, most likely 
arisen through gene duplication94, codes for yet another closely related Mx protein: Mx2 (in 
mice) or MxB (in humans). This protein, however, is very different from Mx1/MxA in that until 
recently there has not been any antiviral function associated with it. Mx genes can be found 
in all mammals but also in many other species like birds and fish95,96.  
 
1.3.1 Structure and function 
 
Mx proteins belong to the dynamin family of large GTPases. They resemble the structure of 
cellular dynamin97, which is a protein involved in endocytosis. According to the crystal 
structure, Mx proteins have a globular GTPase domain (G domain) head and an elongated 
stalk consisting of five α-helices. G domain and stalk are linked via a bundle-signaling 
element (BSE) built of three α-helices98, which confers structural changes of the G-domain 
after GTP hydrolysis to the stalk. Between the α3- and α4-helix the unstructured L4 loop is 
localized. This loop has been shown previously to be involved in the recognition of Thogoto 
vRNPs and to be important for the antiviral activity against IAV and La Crosse virus99-101. If 
this loop is replaced in Mx1 with the one from MxA, this chimeric protein is then able to inhibit 
THOV replication100. 
MxA’s expression is induced exclusively by interferon type I and III. MxA localizes to the 
cytoplasm and there is evidence that it associates with the smooth endoplasmic reticulum 
(smooth ER) 102. Mx1, however, localizes to the nucleus and forms distinct dots, which were 
shown to be closely associated with promyelocytic leukemia (PML) nuclear bodies103. PML 
bodies form distinct nuclear dots 5-15 in number with a diameter of 0.1-1 µm104. The function 
of PML is highly diverse ranging from tumor suppression105 over regulating apoptosis106 to 
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the protection against a variety of viruses107-109. There are two isoforms of MxB, a longer 
isoform, which harbors a nuclear localization signal (NLS) and the other isoform lacking this 
NLS. The former therefore localizes to the nucleus, but interestingly to the cytoplasmic face 
of the nuclear envelope and the latter is dispersed throughout the cytoplasm.  
 
MxA exhibits potent antiviral activity against many RNA110 viruses, most thoroughly 
investigated Thogotovirus (THOV), a member of the bunya virus family, and IAV, but also 
two DNA viruses (Hepatitis B Virus (HBV) and African Swine Fever Virus (ASFV))111,112. It is 
interesting to note here, that despite MxA being localized to the cytoplasm it inhibits IAV and 
THOV, viruses that replicate in the nucleus, but also viruses whose replication takes place in 
the cytoplasm, whereas Mx1 only inhibits viruses which replicate in the nucleus. MxB on the 
other hand is only restricting HIV-1 and HSV-1. In 2013, Goujon and colleagues were able to 
show for the first time that human MxB indeed harbors anti-HIV activity113 and this year MxB 
was characterized to be a Herpes virus restriction factor114. 
When cells are stimulated with interferon-α2, endogenous MxA is present as a tetramer in 
the cell115. There are several mutants available, which lock MxA in a defined oligomeric 
state115: monomeric (M527D, L612K) or dimeric (L617D, R640A) variants, which retain their 
antiviral potential. Inactive GTPase domain mutants, abolishing GTP-hydrolysis function only 
or in combination with GTP-binding, are additionally available (Δ81-84, T103A, D250N, 
D253N). It has also been shown in vitro under high salt concentrations that MxA can form 
higher order oligomers and ring-like structures similar to dynamin116. 
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Fig. 1.4. Structural comparison of human MxA, MxB and dynamin. A) Schematic representation of 
the indicated proteins and their length in number of amino acid residues. G domain: GTPase domain, 
BSE: bundle-signaling element, α1-5: α-helices 1-5, NLS: nuclear localization signal, PH: pleckstrin 
homology domain, PRD: proline-rich domain. B) Crystral structures visualized with Pymol (RCSB 
protein database ID: MxA: 3szr, MxB: 4whj, dynamin: 3zvr) 
 
1.3.1 Mx proteins and IAV 
 
MxA and Mx1 inhibit their target viruses at different stages of the viral replication cycle. 
Focusing on IAV and bunyaviruses, Mx1, as opposed to MxA, generally inhibits earlier steps 
in the virus replication cycle. More specifically, in the presence of Mx1 primary transcription 
of both viruses is already inhibited. On the other hand, MxA does not interfere with primary 
transcription or the export of the primary transcripts117, but targets a step after viral protein 
synthesis. MxA associates with IAV and bunyavirus nucleoproteins, but the mechanisms of 
action are not completely understood to date118,119. For bunyaviruses, however, it is thought 
that binding of MxA to the nucleoprotein (N) leads to its sequestration and missorting, which 
makes it inaccessible for the viral replication complex. Intriguingly, if the localization of MxA 
MxA
MxB
Dynamin
side view top view bottom view
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is artificially changed from cytoplasmic to nuclear, IAV primary transcription is inhibited as 
seen with Mx1120. 
MxA efficiently inhibits the replication of a number of different IAV strains. Avian strains of 
IAV are generally more sensitive while human IAV strains have adapted to MxA and exhibit 
at least partial resistance121,122. Recent evidence through mutational scanning of single 
amino acid residues indicates that NP of IAV represents the target of MxA122,123. This was 
shown by the introduction of amino acid substitutions in the NP of MxA-sensitive H5N1 IAV 
strain originating from the resistant pH1N1 strain. These substitutions gradually decreased 
the sensitivity of H5N1 NP to MxA in the mini replicon assay122. 
The GTPase domain of Mx1 and MxA are highly conserved and also essential for the 
proteins antiviral activity. If the capability to hydrolyse GTP is abrogated the antiviral effect is 
lost as well. Intriguingly, the question of what the functions of GTP-binding and -hydrolysis 
are is still not resolved. On the other hand, MxB’s G-domain function is dispensable for its 
anti-HIV activity124 but crucial for the inhibition of HSV1 and HSV2 replication114. 
 
1.4 Cellular RNA helicase UAP56 (or DDX39B) 
 
UAP56 belongs to the DEAD-box family of RNA helicases. This is a family of RNA helicases, 
which are found in all eukaryotes and also most prokaryotes. The name originates from a 
conserved motif consisting of the four amino acids aspartic acid (Asp, D), glutamic acid (Glu, 
E) and alanine (Ala, A) in the order D-E-A-D125-127. This family of ATP-dependent RNA 
helicases are involved in a variety of processes ranging from unwinding of dsRNA, nuclear 
RNA export, RNA folding, remodeling of RNA-protein complexes to performing RNA 
chaperone functions and being involved in splicing and translation initiation125. 
UAP56 in particular is a nucleo-cytoplasmic shuttling protein128, since it is part of the 
transcription export (TREX) complex129 and involved in the nuclear export of spliced cellular 
mRNAs130. UAP56 is composed of two globular domains, which are connected by a flexible 
linker131 and is intracellularly present as a dimer. In humans, there is a closely related gene 
coding for the UAP56-Related Helicase URH49 (or DDX39A) 132. The two proteins share 
90% sequence homology, however, the DEAD-box RNA helicase motifs are fully conserved. 
The least conserved parts can be found at the N-terminus128. The two proteins have very 
similar functions but they differ in the expression level. In most tissues UAP56 mRNA levels 
are much higher than URH49 levels132.  
 
In the context of IAV infection it has been shown that UAP56 knock-down results in reduced 
viral titers (as well as URH49 knock-down, although to a lesser extent)133 and impaired 
mRNA export of several viral genome segments134. Additionally, dsRNA accumulation can be 
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observed in the cytoplasm133. This may indicate that UAP56 plays a role in preventing the 
interferon system from being activated through inhibition of dsRNA formation. 
UAP56 also appeared as a potential hit in an siRNA screen, where it was screened for loss 
of anti-IAV activity of MxA through a knock-down of a panel of different cellular proteins135. 
UAP56 (and URH49) have further been shown to interact with Mx157, MxA57 and UAP56 also 
interacts with free (not bound in the vRNPs) NP136,137. UAP56-NP complexes, however, 
dissociate when challenged with increasing amounts of RNA136 and NP-RNA complexes are 
formed. This could indicate a chaperone function for UAP56 to prevent the aggregation of NP 
and promote the assembly of NP molecules onto the elongating vRNA during replication. It 
has indeed been shown in 2011 that long nascent cRNA production in vitro was stimulated in 
the presence of UAP56 as opposed to NP alone29. So as a model the authors proposed a 
chaperone function of UAP56, whereby NP is co-replicationally added to the growing cRNA 
chain to prevent the formation of secondary structure formation and therefore premature 
termination of cRNA synthesis. 
 
1.5 Aims of this work 
 
MxA is an interferon- induced protein, which potently protects cells from invading pathogens, 
such as, most importantly for this work, IAV. The Mx1 gene was identified more than 50 
years ago and (human) MxA’s high antiviral potential against IAV and vesicular stomatitis 
virus (VSV) was first shown in 1990138. In the following decades a lot of work was performed 
to shed light on the antiviral mechanism of MxA but to so far the exact mechanism of action 
on the molecular level still remains elusive. The viral target protein of MxA is thought to be 
NP and there has also been experimental evidence of the involvement of the cellular RNA 
helicase UAP56 in MxA’s antiviral function. 
We therefore investigated the interplay between the three proteins MxA, NP and UAP56, with 
respect to the importance of the proteins’ stoichiometry and/or enzymatic activity. We also 
aspired to map the binding sites in each protein to its two interactors. We further aimed at 
finding viral and cellular determinants of the antiviral action of Mx proteins also in conjunction 
with UAP56. Additionally, we investigated the antiviral potential of MxB against IAV, a protein 
closely related and very similar in structure to MxA. 
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2.1 Abstract 
 
Mx proteins are a group of proteins with potent antiviral potential. Different Mx proteins 
localize to different subcellular compartments and also inhibit different viruses in seemingly 
different ways. Human MxA localizes to the smooth endoplasmic reticulum in the cytoplasm 
and exerts potent anti-IAV activity at a step after primary transcription and export of viral 
mRNAs. However, if it is artificially re-localized to the nucleus IAV replication is still inhibited 
but at an earlier step before primary transcription. This inhibition of primary transcription is 
also seen in cells expressing Mx1, a mouse homolog of MxA localizing to the nucleus. 
However, mouse Mx1 does not inhibit IAV when mis-localized to the cytoplasm. We thus 
investigated the structurally very similar human MxB protein, which is primarily localized to 
the cytoplasm and the cytoplasmic face of the nuclear envelope in terms of its antiviral 
potential when located to the nucleus. 
We showed that nuclear MxB inhibits IAV replication at the level of or before primary 
transcription similar to mouse Mx1. This suggests a conserved antiviral mechanism between 
different Mx proteins, which is dependent on the exact subcellular localization. We further 
observed the capability of TMxB to bind to IAV NP. This and the fact that also wildtype MxB 
co-precipitated with NP suggests that NP-binding is not sufficient to exert anti-IAV activity. 
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2.2 Introduction 
 
Mx proteins are dynamin-related GTPases that play key roles in the interferon type I and III 
mediated innate immune response against viruses (reviewed in96). They interfere with the 
replication of many RNA and DNA viruses by inhibiting early steps of their life cycle. The two 
MX genes (MX1 and MX2) of the human genome encode the two proteins MxA and MxB 
(also designated Mx1 and Mx2). MxA protein restricts a broad spectrum of viruses, primarily 
negative-stranded RNA viruses and DNA viruses but also some positive-stranded RNA 
viruses (for a review see95). The subcellular localization determines in part the antiviral 
specificity of Mx proteins120,139. MxB has recently been shown to inhibit the replication of 
primate (non-human and human) lentiviruses and herpesviruses113,114. Mammalian Mx 
proteins accumulate in different subcellular compartments. Human MxA accumulates in the 
cytoplasm and has been reported to be associated with the plasma membrane as well as the 
smooth endoplasmic reticulum102,140. MxB exists as at least two isoforms of 715 and 690 
amino acids in length. The longer isoform represents the full-length form including the amino 
terminal NLS, while the shorter isoform engages the second methionine (M26) downstream 
of the NLS as translation start site141,142. The full length MxB is localized primarily on the 
cytoplasmic face of the nuclear membranes but when expressed ectopically it can also be 
found in the cytoplasm or in the nucleus in a granular pattern in the heterochromatin region 
beneath the nuclear envelope114,142,143. The short isoform is expressed in the cytoplasm144,145. 
The mouse genome carries two Mx genes encoding nuclear Mx1 and cytoplasmic Mx293,146. 
Mouse Mx1 protein contains an NLS in the carboxy-terminal region and is thus exclusively 
expressed in the cell nucleus93,147. Mouse Mx1 exclusively inhibits members of the 
orthomyxovirus family including influenza A virus (IAV), which replicates in the cell nucleus. 
By contrast, Mx2 restricts vesicular stomatitis virus (VSV) and Hantaan virus, both negative-
stranded RNA viruses replicating in the cytoplasm146,148,149. Intriguingly, MxA restricts not only 
various RNA viruses replicating in the cytoplasm such as VSV, La Crosse virus or Semliki 
forest virus (SFV) but also several members of the orthomyxoviruses, including IAV 
(reviewed in95,96). Mx proteins require a functional G-domain to inhibit Mx-sensitive viruses; 
exceptions are MxB when targeting lentiviruses113 and MxA blocking HBV150. Although the 
viral targets of Mx proteins are known for many Mx-sensitive viruses to be nucleoproteins (or 
vRNP complexes) or nucleocapsids (reviewed in95), the molecular mechanism(s) of action of 
Mx proteins remain to be elucidated. In the case of IAV the prevailing model predicts that 
Mx1 as well as MxA attach to the IAV vRNPs by forming oligomeric “ring-like” structures 
thereby blocking the activity of the viral polymerase151-153. However, this mode of action does 
not explain the pronounced inhibition of the IAV based mini-replicon system where replication 
occurs from vRNPs formed in the nucleus154. Hence, MxA must act at an additional step of 
the viral replication cycle. We have recently shown that the mouse Mx1 as well as human 
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MxA bind to the cellular DEAD-box RNA helicase UAP5657. Intriguingly, UAP56 is required 
for efficient replication of IAV at multiple steps of the viral life cycle, which include predicted 
efficient export of viral RNAs (as for other viruses155,156) to the cellular translation machinery 
as well as a chaperone function for newly synthesized NP to be incorporated into newly 
formed vRNPs in the nucleus of infected cells29,57,133,137. Hence, it is conceivable that MxA 
targets the UAP56-NP complex in the cytoplasm and thereby restricting the availability of NP 
for the replication process by a yet to be identified mechanism. MxA is thought to exert a 
gate keeper function in the cytoplasm, blocking or modifying NP of incoming vRNPs and/or 
newly synthesized NP in the cytoplasm of infected cells. Similarly, for MxB evidence also 
points to a gate keeper function by preventing the nuclear import of genomic DNA of human 
lentiviruses and herpesviruses into the nucleus114,157.  
The fact that Mx proteins inhibit a wide variety of RNA and DNA viruses at different 
subcellular locations raises the question whether (i) Mx proteins act via a largely common 
mechanism and the observed virus specificity is a consequence of distinct subcellular 
localization or (ii) Mx proteins act through distinct molecular mechanisms. 
When MxA was ectopically expressed in the nucleus by virtue of an artificial NLS attached to 
its amino terminus (TMxA) it exhibited a pronounced restriction of IAV already at the stage of 
primary transcription of viral mRNAs120, the same phenotype which is seen in Mx1-
expressing cells. However, the cytoplasmic variant of Mx1 mMx(R614E) that lacks a 
functional NLS is not able to adopt the activity of MxA. Mx1(R614E) exhibited no antiviral 
activity neither against IAV nor VSV139. These data suggest that the mode of action of human 
MxA and mouse Mx1 differ and that MxA has the ability to block IAV in the cytoplasm as well 
as in the nucleus by employing distinct mechanisms. Nevertheless, this study did not take 
into account that Mx proteins may have to localize to specific sites in the cytoplasm in order 
to exert antiviral activity against a given virus. Hence, it may be possible that the different Mx 
proteins from different mammalian species act by using the same mechanism. 
To address this issue we made use of human MxB predominantly accumulating in the 
perinuclear region. This protein exerts antiviral activity against HIV and herpesviruses but not 
IAV. We reasoned that if our hypothesis was correct a nuclear form of MxB should restrict 
IAV replication. To this end we chose the NLS of the large T antigen of SV40, since 
cytoplasmic MxA directed to the nucleus by the same NLS exhibits pronounced anti-IAV 
activity. We show here that MxB targeted to the nucleus indeed blocks IAV replication at a 
step prior to primary transcription. 
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2.3 Experimental procedures 
 
2.3.1 Cell lines 
 
All cell lines were cultured in DMEM supplemented with 10% FCS, 1 mg/ml 
Penicillin/Streptomycin and 2 mM GlutaMAXTM (Thermo Fisher Scientific) (complete DMEM) 
at 37°C and 5% CO2. HEp-2 (HeLa-derived human epithelial cells) and HEK-293T (human 
embryonic epithelial kidney cells) were purchased from ATCC. 
 
2.3.2 Plasmids 
 
As previously described MxA wt cDNA was cloned into pcDNA3.1(+)neo (Invitrogen)158. 
MxA(R640A) cDNA in pcDNA3.1(+)neo plasmids was kindly provided by Georg Kochs, 
Freiburg, Germany. MxA mutant D250N was generated using the QuikChange II Site-
Directed Mutagenesis Kit (Agilent). Primers were designed using 
http://www.bioinformatics.org/primerx/ with the QuikChange protocol. 
pCAGGS-NP plasmid (NP cDNA derived from A/Thailand/1(KAN-1)/2004 (H5N1), was kindly 
provided by Martin Schwemmle, Freiburg, Germany. 
MxB cDNA with an N-terminal FLAG-peptide sequence or MxB cDNA with an N-terminal 
large T antigen NLS peptide plus FLAG-peptide were cloned into pcDNA3.1(+)neo 
(Invitrogen) using the NotI and XbaI restriction sites. FLAG-Mx1 or FLAG-Mx1(K49A) 
encoding plasmids were previously described159. TMx1 encoding plasmid was described 
previously139. Mutants Mx1(R614E) and TMx1(R614E) were generated using the 
QuikChange II Site-Directed Mutagenesis Kit (Agilent). Primers were designed using 
http://www.bioinformatics.org/primerx/ with the QuikChange protocol. 
 
2.3.3 Viruses 
 
Infection experiments were carried out using Influenza A/Seal/Massachusetts/1/1980 H7N7 
(≡rSC35M). Infections were carried out in PBS supplemented with 0.02 mM Mg2+, 0.01 mM 
Ca2+, 0.3% BSA and 1% penicillin/streptomycin (PBSi) for 1 h at 37°C. Inoculum was 
removed, cells were washed with PBS and DMEM supplemented with 20mM HEPES, 0.2% 
bovine serum albumin (BSA), 1 mg/ml Penicillin/Streptomycin and 2 mM GlutaMAXTM 
(Thermo Fisher Scientific) (piDMEM) was added. 
 
2.3.4 Immunofluorescence assay 
 
Nuclear MxB variant blocks influenza A virus replication 
21 
 
Cells were seeded in 24-well format on glass cover slides. After transfecting with jetPRIME® 
(Polyplus transfection), cells were fixed with 3% paraformaldehyde (PFA) in PBS for 10 min 
at RT and permeabilized with 0.1% or 0.5% Triton-X100 in PBS for 10 min at RT. Staining 
was performed in PBS with 5% goat serum for 1 h at RT (mouse α-MxA (hybridoma ab143, 
1:5), mouse α-MxB (Santa Cruz, sc 271527, 1:50), mouse α-FLAG M2 (Sigma, F1804, 
1:1000), rabbit α-PML (Bethyl laboratories, A301-167A, 1:500). 
2.3.5 Minimal replicon reconstitution assay 
 
The mini replicon assay has been described before154. Basically, pcDNA3.1(+)neo vectors 
harboring cDNA sequences of the viral polymerase subunits PB1,PB2 and PA and viral NP 
derived from the A/Thailand/1(KAN-1)/2004 (H5N1) strain were transfected into 293T cells. 
Additionally, the firefly luciferase (FFLuc) reporter plasmid pPOLI-Luc-RT (Zimmermann et 
al, 2011) and the constitutively active Renilla reniformis luciferase (RRLuc) plasmid pRL-
SV40-Rluc (Promega) as a read-out and for transfection efficiency were co-transfected using 
jetPRIME® (Polyplus transfection) according to the manufacturer’s instructions. 10 ng PB1, 
PB2 and PA and 50 ng NP, FFLuc and RRLuc plasmids plus varying amounts of plasmids 
coding for Mx proteins were transfected. For the read-out, cells were lysed 24 h after 
transfection in 60 µl 1X passive lysis buffer and incubated at room temperature for 15 min on 
a shaker. A dual-luciferase read-out was performed using the Dual-Luciferase® Reporter 
Assay System (Promega). 15 µl lysate was mixed with 45 µl LARII and immediately read on 
a Perkin Elmer Envision 2104 plate reader for the Firefly luciferase signal and additional 
45 µl Stop&Glo was added for the Renilla luciferase read-out. 
 
2.3.6 Cell-Titer-Glo assay 
 
293T cells were transfected and 48 h post transfection half the volume of the medium was 
aspirated. An equal volume of Cell-Titer-Glo reagent (as medium was aspirated) was added 
to the wells, incubated for 2 min at room temperature on a shaker and additional 10 min 
without shaking and luminescence was measured on a Perkin Elmer Envision 2104 plate 
reader. 
 
2.3.7 Co-immunoprecipitation (co-IP) 
 
HEp-2 cells were transfected with ViaFectTM (Promega) according to the manufacturer’s 
instructions. 24 h post-transfection cells were lysed in 300 µl lysis buffer (20 mM Tris-HCl pH 
7.5, 150 mM NaCl, 5 mM MgCl2, 50 mM NaF, 1 mM Na3VO4, 1% NP-40, 50 mM β-
glycerophosphate, 100 nM iodoacetamide, 1x Roche cOmplete Protease Inhibitor Cocktail) 
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in the dark on ice for 30 min. Lysates were homogenized using QiaShredder columns 
(Qiagen). 100 µl of each lysate was incubated with antibody (α-NP (in-house, 50 µl, HB65, 
hybridoma) at 4°C over night on a rotating wheel. 15 µl lysate was used for the whole cell 
lysate (WCL) control. 20 µl Dynabeads protein G magnetic beads (Thermo Fisher Scientific) 
per sample were pre-adsorbed over night at 4°C on a rotating wheel using untransfected 
HEp-2 cell lysate. Pre-adsorbed beads were washed once with lysis buffer and incubated 
with the lysates for 1 h at 4°C on a rotating wheel. Beads were washed once with 1 ml 
followed by five times 0.5 ml lysis buffer. Beads were briefly vortexed in between the washing 
steps. Proteins were eluted from the beads with 20 µl 1x Laemmli buffer at 95°C for 10 min. 
15 µl WCL/IP sample was loaded on a 10% SDS-PAGE gel and analysed by Western blot 
(α-NP (rabbit serum, in-house, 1:10’000), α-FLAG (mouse, Sigma, F-3165, 1:1000). 
 
2.3.8 qRT-PCR 
 
293T cells were transfected using jetPRIME® (Polyplus transfection) according to the 
manufacturer’s instructions. 24 h post-transfection cells pre-treated for 1 h with 100 µg/ml 
cycloheximide (CHX) or DMSO. Cells inoculated with virus in PBSi for 1 h at 37°C with 
rSC35M or SFV V42 at MOI5. The inoculum was aspirated and piDMEM was added. 5 hpi 
the medium was removed and cells were lysed with 200 µl TRIzolTM reagent (Thermo Fisher 
Scientific) per well of a 24-well plate. After the addition of 40 µl chloroform the samples were 
mixed thoroughly by inverting the tubes several times and centrifuged at 13’000xg at 4°C for 
15 min. The resulting upper aqueous phase (~120 µl) was transferred to a new tube and 
RNA extraction was subsequently performed using the RNeasy Mini Kit (Qiagen) starting 
with the addition of 1 volume of 70% EtOH. cDNA synthesis was performed with 1 µg RNA 
using SuperScriptTM III Reverse Transcriptase (Thermo Fisher Scientific) and random 
primers. The qPCR reaction was performed with 2.5 µl of the 1:10 diluted cDNA and 
EvaGreen® fluorescent nucleic acid dye in a total volume of 20 µl. The cycling conditions 
were as follows: initial denaturation: 95°C for 5 min, denaturation: 95°C for 15 sec, annealing 
and extension: 60°C for 60 sec. A dissociation step starting at 55°C was added in the end to 
confirm the specificity of the primers. The primer sequences are: rSC35M PB2 forward 
primer: 5’-GCAATGGGCTTGAGGATT, rSC35M PB2 reverse primer 5’-
CAATCTCCTGGTTGCCTT. GAPDH forward primer: 5-CTGGCGTCTTCACCACCATGG, 
GAPDH reverse primer 5-CATCACGCCACAGTTTCCCGG. Fold change of PB2 mRNA 
normalized to GAPDH mRNA was calculated according to160. In short: first ΔCt was 
calculated (Ct(CHX) - Ct(DMSO)) of a given sample, then ΔΔCt was assessed (ΔCt(Mx)- 
ΔCt(mCherry)) and the final values for plotting were shown as 2^(-ΔΔCt) (in percentage). 
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2.4 Results 
 
We first tested whether full-length MxB encoding the NLS of the large T antigen at its amino 
terminus would be expressed in the cell nucleus (Fig. 2.1 A). We transiently transfected 
HEp2 cells with plasmids coding for MxB (negative control), FLAG-tagged TMxB, FLAG-
tagged Mx1, the cytoplasmic mutant Mx1(R614E) lacking a functional NLS, or the FLAG-
tagged mutant TMx1(R614E) redirected to the nucleus. As expected, TMxB accumulated in 
the nucleus forming different size speckles. Mx1 and the redirected mutant TMx1(R614E) 
showed a very similar punctuated pattern in the nucleus, omitting the nucleoli. The Mx1 
mutant lacking a functional NLS accumulated predominantly in a punctate pattern in the 
cytoplasm. Since Mx1 assemblies have often been observed to be distributed in juxtaposition 
to PML bodies in the nucleus103,161, we co-transfected HEp-2 cells with plasmids encoding 
Flag-tagged TMxB, TMx1, TMx1(R614E) or Mx1 and immuno-stained PML bodies and the 
FLAG peptide in parallel. Indeed, independent of the NLS used (heterologous or 
endogenous) PML bodies were often found next to Mx1 assemblies (Fig 2.1B). 
Next, we tested whether TMxB would exert antiviral activity against IAV. To this end, we 
transfected HEK293T cells with plasmids encoding MxB wt, TMxB and MxA or with the 
control plasmids coding for mCherry or GST and infected them 24 h post transfection with 
0.01 MOI of the A/Seal/Massachusetts/1/1980 (H7N7) strain of IAV. 24 h post infection the 
culture supernatants were harvested and subjected to plaque assay analysis (Fig. 2.2A). 
Surprisingly, TMxB expression restricted IAV to a similar extent than MxA, resulting in a 50 
fold reduction of viral titers. Cell viability assays performed in parallel revealed that the 
observed reduction in titers was not due to possible cytotoxic effects of TMxB expression 
(Figure 2.2B). 
In order to corroborate the antiviral activity of TMxB against IAV we tested its activity using 
the Kan1 based mini replicon system121. HEK293T cells were co-transfected with increasing 
amounts of plasmids (22ng, 66ng, 200ng and 600ng) encoding either mCherry (negative 
control), wild type MxA, the inactive G-domain mutant MxA(D250N), wild type mouse Mx1, 
the cytoplasmic mutant Mx1(R614E), Mx1 with the amino terminal NLS TMx1, or 
TMx1(R614E) together with plasmids encoding PB1, PB2, PA, and NP of the 
A/Thailand/1(KAN-1)/2004 (H5N1) strain, Renilla luciferase under a constitutive promoter 
and the firefly luciferase reporter. The data clearly indicate that TMxB restricted IAV 
replication at least as strongly as MxA while MxB showed only marginal activity at high 
concentration of the transgene (Fig. 2.2C). As expected the G-domain mutant MxA(D250N) 
and the cytoplasmic variant of Mx1 Mx1(R614E) exhibited no inhibitory activity against IAV. 
Mx1 and TMx1 exerted a very strong inhibition of the mini-replicon driven reporter gene 
expression. Surprisingly, however, TMx1(R614E) over-expression only marginally affected 
efficiency of the mini replicon system. The reason for this observation is not clear and 
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contradicts previously published data obtained in mouse 3T3 cells139. Since Mx proteins 
which localize to the nucleus such as Mx1 and TMxA inhibit IAV replication at or before 
primary transcription of viral mRNAs117,139, we tested whether this is also the case for TMxB. 
We transiently transfected HEK293T cells with plasmids encoding mCherry, GST, Mx1, the 
G-domain mutant Mx1(K49A), MxA, MxB or TMxB and infected the cells with 5 MOI of the 
avian strain rSC35M for 6 hours in the presence or absence of cycloheximide (CHX). In the 
presence of cycloheximide IAV vRNPs are still able to enter the nucleus and to produce viral 
transcripts by the vRNP-associated viral polymerase. However, later steps are blocked by 
the translational inhibition exerted by cycloheximide162. Overall mRNA levels are thus 
reduced in CHX- versus DMSO-treated samples since the viral proteins PB1, PB1, PA and 
NP, which are crucial for viral genome replication, are not translated. As expected mRNA 
levels are 35- to 100-fold lower in CHX-treated samples in contrast to DMSO-treated controls 
(data not shown). Synthesis of viral mRNA was determined by RT-qPCR with primers 
specific for PB2. Indeed, TMxB inhibited viral RNA synthesis at a step prior to or during 
primary transcription to a very similar extent as Mx1 (Fig 2.3B). As expected, Mx1(K49A), 
lacking a functional G-domain, failed to inhibit viral mRNA synthesis in the presence or 
absence of cycloheximide (Fig. 2.3A). 
We next tested whether MxB has the capacity to form stable complexes with NP. We 
transiently transfected HEp-2 cells with plasmids encoding FLAG-tagged MxA(R640A), 
wildtype MxB and TMxB together with a plasmid encoding NP of the Kan1 strain. The cells 
were lysed 24 h post transfection and the lysates subjected to co-immunoprecipitation using 
a monoclonal mouse anti-NP antibody. For MxA we employed the dimeric variant 
MxA(R640A) previously shown to exhibit antiviral activity and form a stable complex with 
NP115 Surprisingly, MxB as well as TMxB were efficiently co-precipitated with NP indicating 
that MxB has the capacity to bind NP independently of its subcellular localization (Fig. 2.4A). 
 
2.5 Discussion 
 
The fact that Mx proteins, in particular MxA, are able to exhibit a very broad antiviral 
specificity inhibiting many RNA as well as DNA viruses at different steps of their replication 
cycle suggests that Mx proteins are multi-functional proteins exerting different strategies to 
block viral replication. For instance, MxA blocks the replication of viruses as diverse as VSV 
and HBV at different steps of their life cycle (reviewed in95). Moreover, Mx proteins can be 
found in different subcellular compartments. Human MxA resides in the cytoplasm where it is 
partially associated with internal membranes, in particular the smooth endoplasmic reticulum, 
whereas the human MxB accumulates primarily in the perinuclear region associated with the 
outer membrane of the nucleus but can also be found in the cytoplasm102,114,140,142. 
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In this study we addressed the question whether the apparent diversity of antiviral activities 
of Mx proteins is a consequence of distinct subcellular localizations rather than a multitude of 
molecular mechanisms. To test this hypothesis we employed the human MxB protein with 
well-defined antiviral activities against HIV and HSV but not IAV. We reasoned that if our 
hypothesis were correct redirecting MxB into the nucleus by attaching a classical NLS should 
enable it to block the replication of IAV occurring in the nucleus. Indeed, ectopic expression 
of TMxB inhibited infection with IAV (Fig 2.2A). Moreover, TMxB but not MxB efficiently 
blocked the expression of a luciferase reporter gene driven by the mini-replicon system 
based on the avian IAV strain Kan1 indicating that MxB has the capacity of interfering with 
IAV when located in the nuclear compartment. We also re-tested a cytoplasmic variant of 
Mx1 harboring a mutation, which disrupts the endogenous NLS. This mutant has previously 
been reported to be inactive in the cytoplasm but active when redirected to the nucleus by a 
heterologous amino-terminal NLS. According to our hypothesis of a universal Mx 
mechanism, a cytoplasmic variant of Mx1 should exhibit a similar activity as MxA. We found 
that indeed the cytoplasmic Mx1(R614E) lost its capacity to interfere with IAV replication, 
however, surprisingly the redirected nuclear form TMx1(R614E) did not exhibited strong 
activity either. The R614 residue of the Mx1 NLS resides in the carboxy-terminal part of the 
tripartite BSE that is critical for the proper function of Mx proteins. Hence, we believe that a 
drastic change of a negatively charged K residue to a positively charged E residue reduces 
the antiviral function of Mx1 per se and does not reflect inactivity due to an altered 
subcellular localization. The observed differences between the present study and the study 
by Zürcher and colleagues are most likely due to the use of different cell culture (human 
versus mouse) and assay systems139. 
As expected, expression of the TMxB reduced the synthesis of primary viral PB2 mRNA to a 
similar extent than Mx1 strongly suggesting that TMxB like Mx1 interfered directly with viral 
mRNA transcription by interfering with the activity of the viral transcriptase complex163,164. 
Surprisingly, cells expressing the cytoplasmic MxA also showed reduced levels of viral 
primary transcripts. Evidence suggests that MxA can inhibit IAV replication at two different 
steps (i) during cell entry by blocking incoming vRNPs in the cytoplasm preventing nuclear 
import of vRNPs or (ii) by interfering with the integrity or transport of newly synthesized NP, a 
step following primary viral mRNA synthesis. It is therefore conceivable that in this 
experimental setting overexpression of MxA led to a pronounced block of vRNP import into 
the nuclei of infected cells, preventing initial viral mRNA synthesis.  
Since the antiviral activities of Mx1 and MxA are associated with at least a transient 
interaction with their viral target NP115,122,123,151 it came as no surprise that MxB has the 
capacity to bind NP (Fig 2.4). Intriguingly, we observed that wild type MxB was able to form a 
stable complex with NP as opposed to MxA, which can only stably interact with NP in the 
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dimeric state (variants MxA(R640A) or MxA(L617D)) but not in its wildtype form existing as a 
tetramer. The fact that MxB appears to predominantly form dimers141 most likely explains this 
apparent difference.  
 
Moreover, like mouse Mx1 and human MxA, MxB has also the capacity to form a complex 
with UAP56. The DEAD-box RNA helicase UAP56 is indispensable for IAV replication at 
several steps of its life cycle. Recently, several reports showed that UAP56 acts as a 
chaperone for newly synthesized NP directing it to the site of viral transcription and 
replication in the nucleus where NP acts as a co-factor for the viral polymerase and protects 
the nascent vRNA chains29. Hence it is tempting to speculate that Mx proteins interfere with 
this process by sequestering newly synthesized NP from the replication site. However, firm 
proof for this proposed mode of action of Mx proteins is still lacking.  
Interestingly, wild type MxB which exhibited no inhibitory activity against IAV was able to 
form stable complexes with NP as efficiently as TMxB, which exerts a pronounced restriction 
of IAV. These findings strongly suggest that the ability of MxB to form a complex with UAP56 
and NP is not sufficient for exhibiting antiviral activity. Evidently, an additional factor provided 
in the nucleus but not in the perinuclear region is required for its activity against IAV. 
In this context it is interesting to note that MxB accumulating in the perinuclear region also 
forms stable complexes with UAP56 (Fig 2.4B). Hence, the complex formation of MxB with 
UAP56 may represent an integral functional feature, independent of its activity against IAV. 
Possibly the association with UAP56 is a necessary prerequisite for MxB to inhibit additional 
as yet not identified viruses. The positive selection of amino acid residues at the amino 
terminus of MxB in higher primates, that are not associated with a known antiviral function 
yet, point in this direction165. 
 
Here we report for the first time that nuclear MxB has the potential to restrict IAV replication. 
In the future it would be of great interest to further characterize this antiviral activity on the 
mechanistic level. Also, MxA and MxB are very similar in structure; however, they vary 
greatly in their anti-IAV activity. More insights into the factors that determine this essential 
difference would likely shed more light on the general antiviral mechanism of Mx proteins and 
are thus much sought after.  
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2.1 Mx1 and nuclear MxB (TMxB) are associated with PML bodies. A HEp-2 cells were 
transfected with plasmids coding for wildtype MxB, nuclear MxB (TMxB), wildtype Mx1, 
cytoplasmic Mx1 (Mx1(K614E)) and TMx1(K614E). Cells were fixed and immune-stained as 
indicated. B HEp-2 cells were transfected with plasmids coding for TMxB, Mx1, TMx1 and 
Mx1. Cells were fixed and immuno-stained with the indicated antibodies. PML bodies: 
promyelocytic leukaemia nuclear bodies. 
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2.2 A nuclear variant of MxB (TMxB) shows restriction of IAV replication. A left: Plaque 
assay titration of supernatants harvested from 293T cells transiently transfected with 
plasmids coding for the indicated control protein or Mx proteins and infected with MOI 0.01 
for 24 h. Supernatants were titrated on MDCK cells. Data are represented as mean ±SEM of 
duplicates. Right: expression control. Samples were harvested at the same time as 
supernatants were collected for the plaque assay. Immunostaining was performed using the 
indicated antibodies (bottom panel). B Cell-Titer-Glo cell viability assay. 293T cells were 
transfected as in A and cells were lysed at the same time as supernatant was collected for 
the plaque assay from an identical plate. Luminescence was measured and absolute values 
were plotted. Data are represented as mean ±SEM of duplicates. C Mini replicon assay of 
293T cells transfected with plasmids encoding the mini replicon constituents and increasing 
amounts of mCherry or various Mx proteins. Cells were lysed and a dual luciferase assay 
was performed. Values are presented in percent firefly luciferase activity normalized to 
Renilla luciferase relative to the mCherry control for each condition individually (22ng, 66ng, 
200ng 600ng). Values of mCherry-expressing samples are set to 100%. Data are 
represented as mean ±SEM of duplicates. Western blot analysis was performed on pooled 
lysates for each condition and immunostaining was performed with the indicated antibodies 
(bottom panel).  
 
Fig. 2.3 
A 
B 
α-FLAG 
α-actin 
FLAG-X 
α-GST 
DMSO 
Re
la
tiv
e 
PB
2 
m
RN
A 
pr
od
uc
tio
n 
(%
) 
0 
50 
100 
150 CHX 
Re
la
tiv
e 
PB
2 
m
RN
A 
pr
od
uc
tio
n 
(%
) 
0 
50 
100 
150 
GST - - - - - + - 
31 
Nuclear MxB variant blocks influenza A virus replication  
32 
 
2.3 Primary transcription of IAV is inhibited by TMxB. A 293T cells were transfected with 
plasmids coding for the indicated control or Mx proteins and infected with rSC35M(H7N7) at 
MOI5 for 6 h. RNA was isolated and reverse transcribed into cDNA using random primers. 
RT-qPCR analysis was performed and PB2 mRNA normalized to GAPDH mRNA is shown. 
Cells were pre-treated with 100 µg/ml cycloheximide (CHX) or the same volume of solvent 
(DMSO) for 1 h prior to infection. Infection was carried out in the presence of CHX. Values 
are relative to the mCherry control, which was set to 100%. Data are represented as mean 
±SEM of triplicates. B Western blot analysis of 293T cells transfected and lysed at the same 
time as in A. Immunostaining was performed with the indicated antibodies. 
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2.4 TMxB interacts with Kan1 NP. A HEp-2 cells were transfected with plasmids coding for 
the indicated Mx proteins and either a Kan1 NP-expressing plasmid or the empty vector only. 
Immunoprecipitation was performed with an α-FLAG antibody. IP fractions and WCL samples 
were subjected to Western blot analysis using the indicated antibodies. 
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3.1 Abstract 
 
MxA exerts potent activity against a panel of RNA- and DNA-viruses with influenza A virus 
(IAV) being one of those target viruses. IAV replication is inhibited by MxA through a yet 
uncharacterized mechanism targeting the viral nucleoprotein (NP). Evidence suggests, 
however, that incoming vRNPs as well as a later less defined step between viral protein 
translation of viral proteins and replication are inhibited. Here we show that import of newly 
translated NPs was not affected by MxA. The mechanism of action further appeared not to 
be indirect by separating NP from its chaperone the cellular DEAD-box helicase UAP56. We 
further showed that the potential of MxA to inhibit IAVs of different origin does not correlate 
with its binding strength to the respective NPs. Also, the dimeric state of MxA, as opposed to 
its wildtype tetrameric form, is the determinant of stable binding to viral NP independent of its 
antiviral activity. The enzymatic activities of UAP56 are similarly dispensable to enable 
binding to MxA and NP. Lastly, we found two residues in NP, which are involved in NP 
oligomerization, to abrogate binding to MxA as well as UAP56 when mutated to alanine. Our 
results suggest MxA to modify NP, UAP56 or the NP-UAP56 complex prior to nuclear 
translocation and thereby abrogating functional integrity. 
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3.2  Introduction 
 
The human organism has evolved various means to fight the multitude of pathogens, which 
constantly threaten its health. One of such means is the interferon system, a fast and broadly 
acting defense mechanism present in virtually all human cells. When activated trough 
pathogen recognition the innate immune system induces the expression of a variety of 
interferon stimulated genes (ISGs) with potent activities against a variety of invading 
pathogens. In the context of influenza A virus (IAV) infection there are several well described 
ISG products such as 2′,5′-oligoadenylate synthetase (OAS) and RNase L, protein kinase R 
(PKR) and interferon-inducible transmembrane (IFITM) proteins (reviewed in166). Another 
protein that plays a major role in restricting IAV infections is the myxovirus resistance protein 
1 (MxA). MxA is a cytoplasmic dynamin-like large GTPase, which is induced by interferon 
(IFN) type I (α/β) and type III (λ)112,158,167,168 and although it has been discovered over 50 
years ago92,169 its mechanism of action against IAV is still not very well characterized. The 
crystal structure of MxA reveals an N-terminal globular GTPase-domain (G-domain) and a C-
terminal elongated stalk domain, which is connected to the G-domain via a tripartite bundle 
signaling element (BSE)98,170. In IFN-stimulated cells MxA presents itself as a tetramer115 but 
it has also been shown in vitro to form higher order oligomeric structures116,171. An 
enzymatically active G-domain is indispensable for its antiviral activity159,172,173 however a 
functional role for GTP hydrolysis in relation to MxA function has not been assigned yet. 
A vast effort has been made in the past decades to shed more light on the detailed antiviral 
mechanism of MxA not only against IAV but against a variety of RNA and DNA viruses. For 
Thogoto virus (THOV), an orthomyxovirus virus like IAV, it has been shown that primary 
transcription is inhibited by binding to and blocking the transport of the viral nucleocapsids 
into the cell nucleus174,175. Furthermore, an unstructured loop (loop L4) in the stalk domain of 
MxA has been associated with this function100. This loop also seems to be the determinant 
for antiviral specificity99 and is responsible for the localization of MxA to the smooth 
endoplasmic reticulum (ER)116. Considering the viral replication cycle of IAV (see fig. 3.6), 
one of the earliest steps at which IAV could be inhibited is primary transcription and export of 
the mRNA transcripts. However, it has been shown that these processes are unaffected in 
MxA-expressing cells115,117. Viral replication, on the other hand, is highly reduced. It has 
further been shown, that the viral target protein of MxA is the nucleoprotein (NP)115,123, an 
abundant protein in in the nucleocapsids of IAV virions, which envelops the viral genomic 
RNA segments. If certain residues are exchanged between NPs derived from human and 
avian strains, with human strains generally being more resistant to MxA, inhibition of IAV 
replication by MxA can be altered dramatically122. Binding of viral NP to MxA has additionally 
been shown115, which strengthens the hypothesis of NP being the major target of MxA. 
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Cellular factors are further involved in the antiviral function of MxA. The DEAD-box helicase 
UAP56 (also designated DDX39B) was shown to interact with MxA57. This helicase is part of 
the transcription export (TREX) complex, which is involved among other processes in mRNA 
transcription and nuclear export176. UAP56 is a dimeric nucleo-cytoplasmic shuttling protein 
but it localizes mainly to the nucleus in fixed cells57. There is further evidence that UAP56-
expression is crucial to maintain the antiviral potential of MxA, since MxA loses its activity 
when UAP56 is downregulated135. UAP56 has also been implicated in being a proviral 
factor133 acting co-translationally as a chaperone for IAV NP. This ensures safe transport of 
NP to the nucleus, where it is delivered to viral RNA and supports viral replication29. 
In this work we aimed at resolving the inhibitory mechanism of MxA against IAV in more 
detail. It is currently under debate, whether viral primary transcription is affected in MxA-
expressing cells115,117,177,178 (Fig.2.3A, Martin Schwemmle, personal communication). It is 
clear, however, that MxA engages with viral NP115. This occurs either very early with NP 
incorporated in incoming vRNPs or at a later step after primary transcription with newly 
translated NP. The proposed antiviral mechanism through binding of MxA to incoming 
vRNPs is based on a ring-like model of MxA. This model, however, is solely based on crystal 
structures and in vitro oligomerization assays98,153,170. We thus hypothesized that following 
primary mRNA transcription, nuclear export and translation, the translocation step of newly 
generated viral proteins to the nucleus could be affected in the presence of MxA. 
Additionally, we reasoned that there may be a correlation of the binding strength of NPs of 
various viral strains with the respective MxA-sensitivity of those viral strains. To our surprise 
we were not able to support either of those hypotheses. We further characterized the 
structural and enzymatic features of MxA, NP and UAP56 that contribute to the maintenance 
of their interaction capacities. We have observed that the dimeric state of MxA is sufficient to 
induce binding to NP of active as well as inactive MxA mutants. ATPase and helicase 
functions of UAP56 are negligible for the interaction with MxA and NP. The F412A/R416A 
mutant of H5N1 NP lost MxA- and UAP56-binding capacity. 
 
3.3 Experimental procedures 
 
3.3.1 Cell lines 
 
All cell lines were cultured in DMEM supplemented with 10% FCS, 1 mg/ml 
Penicillin/Streptomycin and 2 mM GlutaMAXTM (Thermo Fisher Scientific) (complete DMEM) 
at 37°C and 5% CO2. HEp-2 (HeLa-derived human epithelial cells), HeLa (human 
adenocarcinoma cells), Vero (African green monkey epithelial kidney cells), HEK-293T 
(human embryonic epithelial kidney cells), MDCK (Madin Darby Canine kidney cells) were 
purchased from ATCC. 
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3.3.2 Plasmids 
 
As previously described MxA wt cDNA was cloned into pcDNA3.1(+)neo (Invitrogen)158. 
MxA(R640A) and MxA(T103A) cDNA in pcDNA3.1(+)neo plasmids were kindly provided by 
Georg Kochs, Freiburg, Germany. MxA mutants Δ81-84, Δ81-84/R640A, T103A/R640A, 
D250N, D250N/R640A, D253N, D253N/R640A, F561A, F561A/R640A, I577A and 
I577A/R640A were generated using the QuikChange II Site-Directed Mutagenesis Kit 
(Agilent). Primers were designed using http://www.bioinformatics.org/primerx/ with the 
QuikChange protocol. 
pCAGGS-NP plasmids (NP cDNAs derived from A/Thailand/1(KAN-1)/2004 (H5N1), swl 
A/California/04/2009 H1N1 (≡pH1N1)), A/Seal/Massachusetts/1/1980 H7N7 (≡rSC35M), 
A/Puerto Rico/8/1934 H1N1 (≡PR8)) were kindly provided by Martin Schwemmle, Freiburg, 
Germany. pcDNA3.1(+)neo-FPV-NP (derived from A/fowl/Dobson(H7N7)), pcDNA3.1(+)neo-
PR8-NP (derived from A/Puerto Rico/8/1934 H1N1) and pcDNA3.1(+)neo-WSN-NP (derived 
from A/Wilson-Smith/1933(H1N1)) were kindly provided by Silke Stertz, Zürich, Switzerland.  
pcDNA3.1(+)neo-UAP56 was described before133. UAP56(K49A) and UAP56(D199A) 
mutants were generated by QuikChange as described above. cDNA of GFP β-sheet 10 or 
11179 plus and unstructured linker sequence of 32 or 25 amino acids, respectively was cloned 
into pcDNA3.1(+)neo. These constructs were designed to be suitable as either N- or C-
terminal protein tags. For the detector fragment consisting of the complementing β-sheets 1-
9, cDNA of GFP1-9 was cloned into pcDNA3.1(+)neo179. To obtain GFP10- or GFP11-tagged 
MxA, NP or UAP56 variants, the respective cDNA was cloned into these vectors using PacI 
and BamHI. 
 
3.3.3 siRNA transfection 
 
Transfection was performed in suspension using Lipofectamine® RNAiMAX Transfection 
Reagent. 30 nM siRNA and 5 µl RNAi max was used per well of a 6-well plate 
(siBAT1/DDX39A: 5’-GAAUAUGAGCGCUUCUCUATT-3’, gene accession: NM_004640). 
24 h post-transfection IAV NP was transfected using ViaFectTM (Promega) according to the 
manufacturer’s instructions. Cells were lysed for co-IP and Western blot analysis 24 h later. If 
DNA and siRNA was transfected simultaneously 500 ng DNA, 30 nM siRNA and 2 µl 
Lipofectamine® 2000 were used per well of a 24-well plate. Cells were lysed 48 h post-
transfection for co-IP and WB analysis. 
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3.3.4 Tripartite split-GFP complementation assay 
 
HEp-2 or HeLa cells were seeded in an ibidi µ-slide 4-well chamber (Cat. No 80427). Cells 
were transfected with 500 ng DNA (180 ng plasmid of each GFP10- or GFP11-tagged 
construct and 90 ng GFP1-9 detector fragment) using ViaFectTM (Promega) according to the 
manufacturer’s instructions. 24 h later growth medium was changed to FluoroBrite DMEM 
medium (Thermo Fisher Scientific) and Hoechst 33342 (1:5000) and analysed at a Leica 
SP5 confocal laser scanning microscope. 
 
3.3.5 Non-denaturing PAGE analysis 
 
Vero cells were seeded in 6-well plates and transfected 24 h later with 2 µg DNA with 
ViaFectTM (Promega) according to the manufacturer’s instructions. Cells were lysed 24 hours 
post-transfection in 200 µl lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM MgCl2, 
50 mM NaF, 1 mM Na3VO4, 1% NP-40, 50 mM β-glycerophosphate, 100 nM iodoacetamide, 
Roche cOmplete Protease Inhibitor Cocktail) in the dark on ice for 30 min. Lysates were 
centrifuget at 13’000xg for 20 min at 4°C and dialysed (20 mM Tris-HCl pH6.8, 10% glycerol, 
5 mM MgCl2, 0.1% CHAPS and 0.5 mM DTT) for 4 h at 4°C using Slide-A-Lyzer MINI 
dialysis devices with a 10K molecular weight cut-off (Thermo Scientific). Samples were again 
centrifuged at 13’000xg for 20 min at 4°C and run on a 4-16% TGX gradient gel (BioRad) 
(running buffer: 25 mM Tris-HCl pH8.3, 192mM glycine, 0.5 mM DTT and 0.1% CHAPS, 
sample loading buffer: 300 mM Tric-HCL pH 6.8, 0.05% bromophenol blue, 50% glycerol) for 
4 h at 4°C with a constant electric current of 25 mA/gel. Gels were incubated in SDS-
containing buffer right before blotting (25 mM Tris-HCl pH8.3, 192 mM glycine and 0.1% 
SDS) for 15 min at room temperature. 
 
3.3.6 Minimal replicon reconstitution assay 
 
The mini replicon assay has been described before154. Basically, pcDNA3.1(+)neo vectors 
harboring cDNA sequences of the viral polymerase subunits PB1,PB2 and PA and viral NP 
derived from the A/Thailand/1(KAN-1)/2004 (H5N1) strain were transfected into 293T cells. 
Additionally, the firefly luciferase (FFLuc) reporter plasmid pPOLI-Luc-RT (Zimmermann et 
al, 2011) and the constitutively active Renilla reniformis luciferase (RRLuc) plasmid pRL-
SV40-Rluc (Promega) as a read-out and for transfection efficiency were co-transfected using 
JetPRIME (Polyplus transfection) according to the manufacturer’s instructions. 10 ng PB1, 
PB2 and PA and 50 ng NP, FFLuc and RRLuc plasmids plus varying amounts of MxA 
plasmids were transfected. For the read-out, cells were lysed 24 h after transfection in 60 µl 
1X passive lysis buffer and incubated at room temperature for 15 min on a shaker. A dual-
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luciferase read-out was performed using the Dual-Luciferase® Reporter Assay System 
(Promega). 15 µl lysate was mixed with 45 µl LARII and immediately read on a Perkin Elmer 
Envision 2104 plate reader for the Firefly luciferase signal and additional 45 µl Stop&Glo was 
added for the Renilla luciferase read-out. 
 
3.3.7 Co-immunoprecipitation (co-IP) 
 
HEp-2 cells were transfected with Viafect (Promega) according to the manufacturer’s 
instructions. 24 h post-transfection cells were lysed in 300 µl lysis buffer (20 mM Tris-HCl pH 
7.5, 150 mM NaCl, 5 mM MgCl2, 50 mM NaF, 1 mM Na3VO4, 1% NP-40, 50 mM β-
glycerophosphate, 100 nM iodoacetamide, 1x Roche cOmplete Protease Inhibitor Cocktail) 
in the dark on ice for 30 min. Lysates were homogenized using QiaShredder columns 
(Qiagen). 100 µl of each lysate was incubated with antibody (α-NP (50 µl, HB65, hybridoma, 
in-house, α-FLAG (0.75 µl, rabbit, Sigma, F7425)) at 4°C over night on a rotating wheel. 
15 µl lysate was used for the whole cell lysate (WCL) control. 20 µl Dynabeads protein G 
magnetic beads (Thermo Fisher Scientific) per sample were pre-adsorbed over night at 4°C 
on a rotating wheel using untransfected HEp-2 cell lysate. Pre-adsorbed beads were washed 
once with lysis buffer and incubated with the lysates for 1 h at 4°C on a rotating wheel. 
Beads were washed once with 1 ml followed by five times 0.5 ml lysis buffer. Beads were 
briefly vortexed in between the washing steps. Proteins were eluted from the beads with 
20 µl 1x Laemmli buffer at 95°C for 10 min. 15 µl WCL/IP sample was loaded on a 10% 
SDS-PAGE gel and analysed by Western blot (α-NP (rabbit serum, in-house, 1:10’000), α-
FLAG (mouse, Sigma, F-3165, 1:1000), α-MxA (ab143, hybridoma, in-house, 1:10)). 
 
3.3.8 Subcellular fractionation 
 
HEp-2 cells were trypsinized and centrifuged at 700xg for 5 min. All following steps were 
performed on ice unless stated otherwise. Trypsin was removed and cells were washed with 
ice-cold PBS. Pellet was lysed for 20 min in 100 µl cytoplasmic extraction buffer (0.5% 
Triton-X100, 5 mM Na3VO4, 20 mM β-glycerophosphate, 10 mM HEPES pH 7.4, 2 mM DTT, 
0.1 mM EGTA, 0.01 mM KCl, 0.01 mM EDTA, 1x Roche cOmplete Protease Inhibitor 
Cocktail) under rotation. Nuclei were sedimented by centrifugation at 3000xg for 5 min. 
100 µl supernatant (cytoplasmic fraction) was transferred into a new tube. Nuclei were 
washed twice in 1.5 ml cytoplasmic extraction buffer for 15 min under rotation. An additional 
washing step with wash buffer (5 mM Na3VO4, 20 mM β-glycerophosphate, 10 mM HEPES 
pH 7.4, 2 mM DTT, 0.01 mM KCl, 1x Roche cOmplete Protease Inhibitor Cocktail) was 
performed for 5 min under rotation. Nuclei were incubated with 20 µl wash buffer, 20 µl 
DNase I (1 U/µl) and 5 µl of 10x DNase I buffer and incubated for 10 min at 27°C under 
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gentle shaking. 5x 10 µl nuclear extraction buffer (1% Triton-X100, 5 mM Na3VO4, 20 mM β-
glycerophosphate, 10 mM HEPES pH 7.4, 2 mM DTT, 420 mM KCl, 1x Roche cOmplete 
Protease Inhibitor Cocktail) was added to the samples and the nuclei were lysed for 15 min 
at RT under rotation. Insoluble components were removed through centrifugation at 6000xg 
for 5 min through QiaShredder columns (Qiagen). The samples were subjected to Western 
blot analysis. 
 
3.4 Results 
 
3.4.1 Assessment of the general binding capacity and localization of MxA, viral NP
 and UAP56 
 
The potential of MxA to inhibit IAV strains of avian origin is generally thought to be much 
higher compared to IAV strains of human origin121-123. It has been shown previously that NP 
is the target of MxA115,123. Thus, we wanted to know whether the binding strength of NP of 
avian versus human origin to MxA correlates with their sensitivity to MxA. We first verified the 
sensitivity of various NPs originating from different avian (A/Thailand/1/2004 H5N1 [Kan1], 
A/FPV/Dutch/1927 H7N1 [FPV], A/Seal/Massachusetts/1/1980 H7N7 [rSC35M]) and human 
(A/California/04/2009 [pH1N1], A/Wilson-Smith/1933 H1N1 [WSN]) strains against wildtype 
MxA in a minimal replicon assay (described in121). 293T cells were transfected with plasmids 
coding for the polymerase subunits PB1, PB2 and PA of the A/Thailand/1/2004 (Kan1 
(H7N7)) strain, Kan1 NP, the reporter firefly luciferase, Renilla luciferase for normalization of 
transfection efficiency and either wildtype MxA or mCherry. A dual luciferase assay was 
performed and the resulting firefly luciferase signal was normalized to the luminescence of 
the Renilla luciferase (expressed under a constitutive simian virus 40 (SV40) promoter). The 
most MxA-sensitive NP thereby was avian Kan1, where replication was reduced to 15% in 
the presence of MxA compared to cells expressing mCherry (Fig. 3.1A). The NP of pH1N1 
exhibited the most resistant, retaining ~60% replication capacity. The sensitivities of the 
three additional NPs, originating from FPV, rSC35M and WSN to MxA were intermediate, 
with WSN being slightly more resistant. The two avian NPs FPV and rSC35M retained ~30% 
replication capacity and WSN NP ~35% (Fig. 3.1A). The two human-derived NPs therefore 
showed more resistance to MxA than the three avian strains. By performing co-IP 
experiments in HEp-2 cells stably expressing MxA(R640A) (HEp-2-MxA(R640A)) and 
transfected with plasmids coding for the above described avian and human NPs we tested 
the binding affinity of NP to MxA. As shown previously115, it is not possible to detect binding 
of wildtype MxA to viral NP (data not shown). In contrast, the dimeric mutant MxA(R640A) 
efficiently co-precipitates with NP. We performed co-IP experiments in HEp-2-MxA(R640A) 
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cells, which were transfected with plasmids encoding the above described NPs. MxA(R640A) 
strongly co-precipitated with pH1N1 NP (Fig. 3.1B, quantification of two independent 
experiments in the lower panel). Kan1 and FPV NPs show very weak interaction with MxA 
and rSC35M and WSN NP performing somewhere in between (Fig. 3.1B). In contrast to our 
expectations the binding strength of the different NP variants did not correlate with the 
sensitivity of the respective IAV strains to MxA. Since UAP56 has also been implied in MxA’s 
antiviral potential we next tested, if there is a correlation in binding strength of NP with 
wildtype UAP56. To this end HEp-2 cells were transfected with plasmids encoding FLAG-
tagged UAP56 or FLAG-mCherry as a negative control together with the previously 
described NPs and a FLAG-immunoprecipitation was performed. To our surprise, we could 
not see a correlation in binding efficiency either (Fig. 3.1C). 
NP is a highly conserved protein and the differences in sequence of NPs from various IAV 
strains are minor. Comparing the PR8 (H1N1) versus Kan1 (H5N1) NP, only 33 out of 498 
amino acids differ, which reflects a sequence identity of 93%. However, the introduction of a 
few amino acid changes can alter the MxA sensitivity of NP dramatically as Mänz and 
colleagues demonstrated122. The introduction of 10 amino acid substitutions from avian 
(Kan1) to human (pH1N1) residues (E53D, R100V, Y289H, R305K, F313V, I316M, T350K, 
R351K, V353I, Q357K) (here labelled Kan1 10x) or only the three amino acid substitutions 
R100V, L283P and F313Y (here labelled Kan1 3x) rendered Kan1 NP 80% replication 
competent in the presence of MxA compared to approximately 15% in the case of wildtype 
Kan1 NP122. When we transfected HEp-2-MxA(R640A) cells with plasmids encoding those 
NP mutants and performed co-IP assays we could actually observe a reduction in co-
precipitation of MxA(R640A) with NP although moderate (Fig. 3.1D). However, for PR8 3x, 
which is the complementary mutant to Kan1 3x and thus harbors the mutations V100R, 
P283L and Y313F, we did not see an increase in binding strength (Fig. 3.1D). 
 
3.4.2 Investigating the capability of MxA to compete for NP binding against UAP56 
 and the effect of reduced UAP56 levels on MxA-NP binding 
 
To gain more insight into the mechanism of action of MxA we aimed at finding the step in the 
viral replication cycle, which is inhibited. Since NP is bound by MxA, we hypothesized that 
MxA might prevent NP to reach the nucleus so that the virus would be unable to perform 
genome replication. To this end we performed sub-cellular fractionation experiments in stably 
GST-, MxA wt- or MxA(R640A)-expressing HEp-2 cells (HEp-2-GST, HEp-2-MxAwt, HEp-2-
MxA(R640A)), which were transfected with plasmids coding for Kan1 NP. In order to clarify if 
NP levels in the nuclear fraction in the presence of MxA are reduced, we subjected the 
nuclear and cytoplasmic fractions to Western blot analysis (Fig. 3.2A). As expected, MxA is 
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only present in the cytoplasmic fraction. However, there is no reduction of NP protein level 
apparent in MxA- versus GST-expressing cells (Fig. 3.2A). If the transport of NP is not 
directly affected, MxA might act more indirectly by separating NP and its chaperone UAP56 
from each other. To address this question, we analysed binding of UAP56 to NP in MxA wt- 
or R640A-expressing cells (Fig. 3.2B and C). FLAG-immunoprecipitation was performed with 
lysates of HEp-2, HEp-2-MxAwt or HEp-2-MxA(R640A) cells transfected with plasmids 
coding for Kan1 NP and either FLAG-UAP56 or FLAG-mCherry and revealed that binding of 
UAP56 to NP is not reduced (Fig. 3.2B). Additionally, by transfecting increasing amounts of a 
plasmid encoding MxA(R640A) we could not observe any change in binding efficiency 
between NP and UAP56 either. However, we were able to detect trimeric MxA-NP-UAP56 
complex formation (Fig. 3.2C, last lane). Assuming that UAP56’s capacity to bind to MxA is 
essential for the antiviral action of MxA but having observed no impaired UAP56-NP binding 
in MxA-expressing cells, we decided to investigate the NP-MxA binding kinetics in cells 
depleted of UAP56 (Fig. 3.2D and E). HEp-2-MxA(R640A) cells were transfected with 
siRNAs against either UAP56 mRNA or a non-targeting control and 24 h later plasmids 
encoding for NPs of different viral strains were transfected (Fig. 3.2D). NP 
immunoprecipitation showed a reduction in co-precipitation of MxA in siUAP56-treated cells 
(Fig. 3.2D). Staining for NP, however, revealed an ample reduction in protein level in 
siUAP56-treated samples, which could account for the observed reduction in MxA binding. 
The involvement of UAP56 in mRNA transcription and export is the obvious explanation for 
this decrease in NP expression. Therefore, we repeated the experiment but transfected the 
siRNA and the plasmids at the same time, giving NP enough time to be expressed before 
UAP56 levels are reduced extensively (Fig. 3.2E). NP expression levels were not affected 
anymore, albeit a loss of knock-down efficiency was observed. The aforementioned 
decrease in NP-MxA binding in UAP56 knock-down samples, however, was not detectable 
anymore. 
 
3.4.3 Molecular determinants of MxA in NP binding and anti-IAV activity 
 
The fact, that we can only see binding of NP to dimeric MxA(R640A) but not wildtype MxA in 
co-IP experiments led us to investigate the NP-binding capacity of other MxA mutants. We 
created mutants with substitutions/deletions in the G-domain preventing the binding of GTP 
(Δ81-84159,180, D250N172) or GTP-hydrolysis only (T103A173, D253N172) (Fig. 3.3A, mutations 
are highlighted in yellow). We also generated a loop L4 mutant (F561A/Y100) (not shown in 
the crystal structure since this loop was deleted for crystallization purposes) and I577A100, a 
residue localized at the third position C-terminal of loop L4. These mutations were all shown 
to render MxA inactive, except for F561Y. To assess whether the dimeric state of MxA, its 
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activity or both are needed to bind to NP we further generated double-mutants harboring the 
R640A substitution in addition to the aforementioned mutations. We started by analyzing the 
oligomeric state of those mutants in Vero cells transfected with plasmids coding for MxA 
wildtype and mutants thereof. By non-denaturing PAGE gel electrophoresis and Western blot 
analysis we could confirm the dimeric nature of the R640A double-mutants (Fig. 3.3B). All 
the other (single) mutants were present as tetramers like wildtype MxA with the exception of 
I577A, running as a dimer even in the absence of the R640A substitution (Fig. 3.3B). 
Unfortunately, we were unable to detect Δ81-84 and Δ81-84/R640A under non-denaturing 
conditions (not shown). 
Next we subjected the MxA-mutants to co-IP analyses in order to monitor binding capacities 
to NP. To our surprise MxA(Δ81-84) and MxA(D250N9, G-domain mutants unable to bind 
GTP, co-precipitated with NP in the wildtype background (Fig. 3.3C). Substitution of the R 
residue at position 640 with an A (R640A) increased the binding strengths of the resulting 
double mutants to similar levels as MxA(R640A). For the MxA(T103A) and MxA(D253N) 
mutants binding can only be observed in the R640A background (Fig. 3.3C). For the loop L4 
mutants we observed similar phenotypes with the exception of MxA(F561A/R640A), which 
co-precipitated with NP to a lesser extent. Interestingly, MxA(I577A) did not bind to NP 
independent of the presence of the R640A substitution and also despite it being dimeric in 
either case. 
We also tested whether these mutants inhibited IAV replication using the Kan1 (H7N7) mini 
replicon system. 293T cells were transfected with the mini replicon constituents alongside 
plasmids coding for the above-mentioned MxA mutants or mCherry as a positive control. 
When assessing the replication efficiency by measuring luminescent signal in a dual-
luciferase assay a 10-fold replication reduction was observed in cells expressing wildtype 
MxA in contrast to the mCherry-expressing cells (Fig. 3.3E). MxA(R640A) showed 
intermediate inhibition potential and reduced replication about 4-fold. Introduction of the 
R640A mutation in the aforementioned GTPase mutants did not reverse the loss of function 
phenotype for any of them. However, for the stalk mutants MxA(F561A/R640A) and 
MxA(I577A/R640A) an increase in antiviral activity was indeed observed in contrast to the 
single mutants MxA(F561A) and MxA(I577), respectively, resulting in an inhibitory capacity 
similar to MxA(R640A) alone (Fig. 3.3E). 
 
3.4.4 Enzymatic activity of UAP56 is not crucial for the binding to MxA and NP 
 
In order to clarify if the enzymatic function of UAP56 is a prerequisite for the MxA-mediated 
inhibition of IAV, we generated an ATPase/helicase-deficient mutant (K95A) or helicase-
deficient mutant (D199A) of UAP56181. It has already been shown previously that wildtype 
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UAP56 is able to bind to MxA57. Co-IP experiments were performed in HEp-2-MxAwt and 
HEp-2-MxA(R640A) cells, which were transfected with FLAG-UAP56 or FLAG-mCherry. We 
immuno-precipitated with an α-FLAG antibody and observed efficient co-precipitation of 
wildtype MxA and thus reproducing the finding from Wisskirchen et al. Additionally we 
showed that MxA(R640A) is able to bind to wildtype UAP56 as well (Fig. 3.4A). When testing 
the two enzymatically inactive mutants UAP56(K95A) and UAP56(D199A) no difference in 
binding capacity to wildtype MxA or MxA(R640A) was apparent (Fig. 3.4A and B). 
UAP56 is a nucleo-cytoplasmic shuttling protein whereas MxA is exclusively localized to the 
cytoplasm128,182. It is therefore expected and it has also been shown that the binding of those 
two proteins is occurring in the cytoplasm57. We thus adapted the tripartite split-GFP 
complementation system179 for the purpose of studying the interaction between MxA, UAP56 
and NP, by tagging the three proteins with either β-sheet 10 or 11 of GFP plus a flexible 
linker (10L-/11L-[protein of interest]). We performed live cell imaging analysis to visualize the 
interaction sites via the reconstituted GFP signal in HeLa cells transfected with the plasmids 
encoding the interactor proteins of interest, the detector fragment GFP1-9 and mCherry, 
which was included as a transfection control. We used the monomeric mutant MxA(M527D) 
as a negative control. UAP56 and NP show an exclusively nuclear interaction signal with the 
exclusion of nucleoli (Fig. 3.4C). As expected, UAP56 and wildtype MxA interact in the 
cytoplasm forming a distinct perinuclear ring-like structure. Assessing the interaction of 
UAP56(K95A) and UAP56(D199A) with wildtype MxA no obvious difference was observed 
(Fig. 3.4C). This indeed suggests negligibility of the enzymatic function of UAP56 for the 
interaction with NP and MxA. Unfortunately, we were unable to study NP-MxA interaction 
since we could not detect any GFP signal with this experimental approach. 
 
3.4.5 NP F412A/R416A substitutions in NP abrogate binding to MxA and UAP56 
 
We next wanted to identify regions in NP required for binding to MxA and UAP56. NP of the 
IAV strains A/HK/483/97 (H5N1) and WSN (H1N1) crystallize as trimers50,51. In vitro NP 
exists in a dynamic equilibrium changing from monomers to trimers and vice versa56,183. 
Single amino acid substitutions were shown to be sufficient for locking NP in the monomeric 
state or at least tipping the balance toward the monomeric form, namely R416A, E339A and 
S165D and also the double mutant F412A/R416A54,58. Employing co-IP experiments we 
assessed the binding of Kan1 NP (H5N1) mutants to UAP56 (Fig. 3.5A) and MxA (Fig. 3.5B). 
HEp-2 cells were transfected with plasmids coding for wildtype Kan1 NP or mutants thereof 
and immunoprecipitation of the FLAG peptide revealed that the only NP mutant abrogating 
binding to UAP56 was NP(F412A/R416A) (Fig. 3.5A). Surprisingly, the R416A substitution 
alone was not sufficient to abolish the interaction with UAP56 (Fig. 3.5A). We could further 
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observe increased binding of E339A (Fig. 3.5A). To examine the binding capacities of 
NP(F412A/R416A) and NP(E339A) to MxA, HEp-2-MxA(R640A) cells were transfected with 
plasmids encoding NP or empty vector. NP was immuno-precipitated and interaction to 
MxA(R640A) was only lost with NP(F412A/R416A). We could again observe higher degrees 
of co-precipitation of MxA(R640A) with the NP(E339A) mutant. The E339 residue lies in the 
insertion groove for the tail loop and is bound by R416, a residue in the tail loop58. To further 
ensure that the mutations indeed render NP (partially) monomeric, we also deployed those 
mutants in the tripartite split-GFP system (Fig. 3.5C) and subjected it to non-denaturing 
PAGE analysis (Fig. 3.5D). For the splitGFP assay HeLa cells were transfected with 
plasmids encoding 10L-/11L-tagged wildtype Kan1 NP or Kan1 NP oligomeric mutants 
together with the detector fragment GFP1-9 and mCherry as a transfection control. For non-
denaturing PAGE analysis Vero cells were transfected with plasmids encoding wildtype Kan1 
NP or the aforementioned oligomeric mutant. Gel electrophoresis under non-denaturing 
conditions followed by Western blot analysis revealed, surprisingly, that only the 
F412A/R416A mutant was at least partially monomeric, even though there was also a distinct 
band running at the expected height of a trimer. Thus, these results could not clarify if F412 
and R416 are the residues involved in binding to UAP56 and MxA or if the oligomeric state is 
the prerequisite for binding instead. 
 
3.5 Discussion 
 
MxA is a potent influenza A virus restriction factor; however, the detailed mechanism of 
action is still under debate. We addressed this issue by studying the interplay between MxA, 
NP, the viral target protein of MxA, and UAP56, a cellular helicase associated with MxA and 
IAV. We found that the dimeric form of MxA binds to NP independently of its activity and we 
were able to identify residues in NP, which lead to a loss of NP- and UAP56-binding when 
mutated. We further showed that the enzymatic functions of UAP56 are negligible in order to 
bind to MxA and NP. Unfortunately, we were not able to characterize the antiviral activity of 
MxA in more detail from a mechanistic point of view. 
  
Remarkably, the binding strengths of various NPs originating from different viral strains to 
MxA do not correlate with the MxA-sensitivity of those IAV strains; in other words, NPs of 
more sensitive strains do not show higher binding capacities to MxA in contrast to NPs of 
more resistant strains (Fig. 3.1). pH1N1 is the IAV strain which shows the highest resistance 
to MxA in our assays (Fig. 3.1A), however, its NP bound the strongest to MxA (Fig. 3.1C). 
We rather observed, at least to some extent, an inverse correlation. We hypothesize that 
NPs of MxA-resistant strains could bind to MxA and thus sequester it. MxA’s normally 
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transient NP-interaction, which allows it to bind to multiple NP with rapid turnover, would thus 
be inhibited. These MxA-bound NPs are likely to be released from UAP56-binding, because 
otherwise UAP56-binding to NP would also be expected to inversely correlate with the MxA-
sensitivities of different viral strains, which we have not seen (Fig. 3.1C). 
 
The impact of MxA expression on the IAV replication cycle is the inhibition of viral genome 
replication (Fig. 3.6) and since NP has been shown to represent the target of MxA122,123, 
translation seems not to be inhibited. We thus analyzed which steps of the IAV infection 
cycle between mRNA translation and replication are targeted by MxA. The obvious 
mechanism of MxA, a cytoplasmic protein, is the prevention of NP translocation to the 
nucleus, where NP is indispensable for replication. We showed, however, that NP levels are 
not reduced in MxA- versus GST-expressing cells (Fig. 3.2A). UAP56’s functional link to IAV 
has been proposed to be a chaperone function for newly synthesized NP29. UAP56 thereby 
delivers NP to the vRNA and stimulates encapsidation of the nascent RNA. We further 
speculated that the chaperone function might prevent NP to engage with cellular RNA, which 
would disable it from binding to viral RNA in the nucleus. We imagined that MxA could bind 
to the UAP56-NP hetero-oligomers and separate them from each other. This separation 
could be achieved through GTP hydrolysis. This would associate a function with the GTPase 
activity of the highly conserved G-domain. However, co-IP experiments revealed that 
UAP56-NP binding is not affected in the presence of MxA (Fig. 3.2B and C), thus, NP-UAP56 
complexes seem to translocate to the nucleus together. This is in line with splitGFP data, 
showing interaction of NP and UAP56 in HEp-2-MxA cells (data not shown). To more 
conclusively determine if UAP56 is indeed exerting a chaperone function on and thus 
preventing NP from binding to cellular RNA, an RNA mobility shift assay might provide 
insights184. 
 
There is evidence that UAP56 positively influences the antiviral potential of MxA135. We 
tested the effect of NP-MxA binding in cells with reduced UAP56 levels. Our results, 
however, are inconclusive (compare fig. 3.2D and E) but they rather support the notion that 
NP-MxA binding remains unchanged in cells transfected with non-targeting versus UAP56-
targeting siRNA. We cannot exclude, though, that residual UAP56 levels are high enough to 
sustain NP-MxA binding. Also, unchanged NP-MxA binding in UAP56 knock-down cells, 
where MxA is predicted to be less active, might not be surprising after all, since differences in 
MxA activity against various IAV strains do not correlate with binding to NP of the respective 
strains either (Fig. 3.1 and122).  
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There is still a debate about the active entity of MxA in term of its oligomeric state. Monomers 
and dimers have been shown to be inactive in mini replicon assays170. This is in contradiction 
with our results, where we show sustained, even though reduced, activity in particular of the 
dimeric form (Fig. 3.3E and115). We reasoned that different expression levels of MxA are the 
reason for these seemingly contradictory results, since we also observed a more pronounced 
inhibition of viral replication with wildtype MxA. The crystal structure of MxA indicates higher 
order oligomer formation, which might even represent ring-like structures similar to 
dynamin97,170. Gao et al. along with others151 therefore propose Mx-rings to form around 
incoming vRNPs, which leads to the retention of vRNPs in the cytoplasm. We, on the other 
hand, only observed tetrameric MxA in cells overexpressing wildtype MxA or stimulated with 
IFN-α2 (Fig. 3.3B and115). Stable complexes of NP with MxA are only formed with dimeric 
MxA (Fig. 3.3C) and the dimeric state (through the introduction of the R640A mutation) even 
increased the antiviral potential of otherwise inactive MxA loop L4/α4-helix mutants to the 
level of R640A-only mutant activity (Fig. 3.3C). Thus, we rather assume higher oligomers to 
be a storage form of MxA and dimeric MxA to be the active entity. Interestingly, the inactivity 
of I577A is reverted in the R640A background and shows the same binding characteristics 
and antiviral activity as wildtype MxA. R640A is a compensatory mutation in this context. It 
has already been suggested that an Alanine at position 577 affects folding100, this, however, 
would imply a loss of antiviral activity. When analyzing the oligomeric state the 
MxA(I577A/R640A) band appeared ‘sharper’ in the non-denaturing PAGE analysis (Fig. 
3.3B). The R640A mutation in MxA has already been proposed to lead to a more tightly 
packed and less flexible molecular structure185 and here this probably has a cumulative effect 
with the I577A substitution on the tertiary structure of MxA. 
 
We showed UAP56-MxA binding to be independent of the enzymatic functions of UAP56. 
UAP56 is a protein with RNA-binding activity and has also been shown to interact with other 
proteins176,186,187. UAP56 recruits the adaptor protein Aly the THO complex to intronless 
mRNA, forming the active TRanscription EXport (TREX) complex, for mRNA nuclear 
export176,188. It was suggested, that the ATPase activity of UAP56 triggers its dissociation 
from the RNA resulting in an Aly/THO/mRNA complex for nuclear export188. Others see the 
functional TREX complex as UAP56/Aly/THO/mRNA189,190. Nevertheless, the ATPase 
function of UAP56 seems to be indispensable for TREX complex formation186. The question 
is thus raised whether ATPase and helicase activity are needed for NP-UAP56 interaction. 
Since we assume, that NP-UAP56 complex formation is taking place co-translationally, 
without the involvement of RNA, we would expect both enzymatic functions to be 
dispensable for NP-binding.  
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We assessed, whether the oligomeric state of NP is a prerequisite for binding to MxA and 
UAP56. It has been shown for H1N1 NP that the double-mutant NP(F412A/R416A) and for 
H1N1 and H5N1 NP that even the single-mutant NP(R461A) is monomeric52,55. We observed 
that Kan1 NP(R416A) did not show a loss of binding phenotype in UAP65 immuno-
precipitation experiments (Fig. 3.5A). NP(F412A/R416A), on the other hand, lost its 
interaction capacity to both MxA and UAP56 (Fig. 3.5A and B). We further showed, that in 
Kan1 NP, the single R416A mutation is not sufficient to render NP monomeric (Fig. 3.5D). 
Kan1 NP(F412A/R416A), however, seemed to be at least partially monomeric (Fig. 3.5D). 
This is not in accordance with Chan et al52, who have seen the R461A mutation to render 
H5N1 NP monomeric. Since the interaction domains of H1N1 and H5N1 NPs are practically 
identical51, we expect them to be very similar between different H5N1 strains as well. These 
differences could thus not be explained by sequence variations. In order to clarify if the 
monomeric state is indeed crucial for interaction, we would want to assess the oligomeric 
states and binding capacities of those two mutants in an H1N1 background by using WSN 
NP. 
 
In summary, we believe that higher order oligomers of MxA represent a storage form and 
that (likely through a viral trigger) MxA dissociates into its active dimeric form. In our current 
model MxA engages with NP-UAP56 complexes and changes the functional integrity of 
either or both proteins in a GTP hydrolysis dependent manner. UAP56-NP hetero-oligomers 
shuttle to the nucleus where these changes are not compatible with genome replication. This 
model does by far not explain all the data we have and further investigations are needed to 
add clarity. 
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3.1 Binding capacities of NPs originating from different viral strains do not correlate 
with their sensitivity to MxA. A HEK293T cells were transfected with plasmids coding for 
the mini replicon constituents (originating from the Kan1[H5N1] strain) and NPs of different 
viral strains together with either mCherry or wildtype MxA. Luciferase activities were 
determined by dual-luciferase read-out. Relative activities of the firefly reporter normalized to 
Renilla are shown in the top panel. Replication capacities are shown in percent (middle 
panel) by normalization of the MxA wt to mCherry values from the top panel. Expression of 
the indicated proteins was confirmed by Western blot analysis of pooled samples for each 
condition using the indicated antibodies (bottom panel). Data are represented as mean 
±SEM of duplicates B Stable HEp-2(MxA R640A) cells were transfected with an empty vector 
control or plasmids coding for the indicated NPs. An NP-immunoprecipitation was performed 
and the IP fractions and the WCL samples were analysed by Western blot (top panel) using 
the indicated antibodies. Quantification of two independent replicates is shown in the bottom 
panel. MxA and NP band intensities of the IP fractions were measured using MultiGauge. 
MxA band intensities normalized to the band intensities NP are plotted. Kan1 NP was set to 
1. Data are represented as mean ±SEM of two independent repeats. C HEp-2 cells were 
transfected with plasmids encoding FLAG-mCherry or FLAG-UAP56 together with plasmids 
encoding the indicated NP. After FLAG-immunoprecipitation the IP fractions and the WCL 
samples were analysed by Western blot analysis using the indicated antibodies. Band 
intensities were measured using MultiGauge. MxA band intensities normalized to the band 
intensities NP are plotted. The highest value was set to 1.00. All the other values are relative 
to 1.00 D Co-IP was performed as in B and calculations as in C. WCL: whole cell lysate
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3.2 Monitoring sub-cellular localization of NP and its binding capacity to UAP56 when 
challenged with MxA(R640A). A HEp-2-GST, HEp-2-MxAwt and HEp-2-MxA(R640A) cells 
were transfected with Kan-1 NP. Cells were lysed under low salt conditions, the nuclei were 
pelleted, washed and under high salt condition lysis was performed. Cytoplasmic and nuclear 
fractions were analysed by Western blot with the indicated antibodies. B HEp-2, HEp-2-
MxAwt and HEp-2-MxA(R640A) cells were transfected with plasmids encoding Kan1 NP and 
either FLAG-mCherry or FLAG-UAP56 as a control. Cells were lysed, a FLAG-
immunoprecipitation was performed and the IP fraction and WCL samples were analysed by 
Western blot using the indicated antibodies. C HEp-2 cells were transfected with plasmids 
coding for Kan1 NP, either FLAG-mCherry or FLAG-UAP56 and increasing amounts of 
MxA(R640A) expression plasmid (100ng, 250ng, 500ng). Cells were lysed and a FLAG-
immunoprecipitation was performed. IP fractions and WCL samples were analysed by 
Western blot using the indicated antibodies. D HEp-2-MxA(R640A) cells were transfected 
with plasmids encoding different NPs as indicated or empty vector. 24 hours post 
transfection cells were transfected with 30 nM siRNA targeting UAP56 mRNA. 48 post siRNA 
transfection cells were lysed and an NP-immunoprecipitation was performed. IP fractions and 
WCL samples were analysed by Western blot using the indicated antibodies. E HEp-2-
MxA(R640A) cells were transfected with siRNA targeting UAP56 mRNA together with 
plasmids coding for Kan1 or WSN NP or empty. 48 hours post transfection cells were lysed 
and an NP-immunoprecipitation was performed. IP fractions and WCL samples were 
analysed by Western blot using the indicated antibodies. WCL: whole cell lysate 
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3.3 The dimeric state of MxA highly increases its binding capacity to NP. A Crystal 
structure of MxA visualized with PyMOL based on Gao et al., Immunity, 2011 (RCSB protein 
data bank ID: 3SZR). The G-domain is coloured in orange, the BSE in red and the stalk in 
different shades of green. B Non-denaturing PAGE analysis of Vero cells transfected with 
plasmids coding for different variants of MxA. Lysates were dialysed and run on a gel under 
non-denaturing conditions. Western blots analysis was performed with an α-MxA antibody. 
Molecular weight of MxA: 75 kDa. C and D HEp-2 cells were transfected with plasmids 
coding for Kan1 NP or empty vector and different variants of MxA as indicated. Cells were 
lysed and an NP-immunoprecipitation was performed. IP fractions and WCL samples were 
analysed by Western blot using the indicated antibodies. C: G-domain mutants. D: stalk 
mutants. Pictures in D are derived from the same membrane with identical exposure 
parameters, irrelevant bands were cut out (cut indicated by vertical line). E 293Ts were 
transfected with plasmids coding for the mini replicon constituents and FLAG-mCherry or 
different variants of FLAG-MxA (except I577A and I577A/R640A, which do not harbour a 
FLAG-tag) (200 ng). A dual-luciferase read-out was performed and firefly reporter activity is 
shown normalized to Renilla luciferase activity (left panel). Data are represented as mean 
±SEM of duplicates. Protein expression is confirmed by Western blot analysis (right panel) of 
pooled samples for each condition using the indicated antibodies. Note: additional bands 
seen on the membrane stained with α-FLAG antibody originate from the previous GAPDH 
and NP staining. WCL: whole cell lysate 
 
B 
IP α-FLAG 
WCL 
FLAG-X 
MxA wt + + + + 
α-MxA 
α-MxA 
α-FLAG 
α-FLAG 
C 
Fig. 3.4 
A 
IP α-FLAG 
WCL 
α-MxA 
α-FLAG 
FLAG-X 
α-MxA 
α-FLAG 
MxA(R640A) + + + + 
10
L-
M
xA
 w
t 
- 
11
L-
U
AP
 w
t 
10
L-
M
xA
(M
52
7D
) 
- 
11
L-
M
xA
(M
52
7D
) 
10
L-
Ka
n1
 N
P 
- 
11
L-
U
AP
 w
t 
mCherry Hoechst GFP complement. Merge 
10
L-
M
xA
 w
t 
- 
11
L-
U
AP
(K
95
A)
 
10
L-
M
xA
 w
t 
- 
11
L-
U
AP
(D
19
9A
) 
57 
The trimeric MxA-NP-UAP56 complex: 
Identifying molecular determinants to unravel their interplay 
58 
 
3.4 ATPase and helicase functions of UAP56 are dispensable for MxA- and NP-binding. 
A and B HEp-2-MxAwt (A) or HEp-2-MxA(R640A) (B) cells were transfected with FLAG-
mCherry or FLAG-UAP56wt or different mutants thereof. UAP56(K95A): ATPase- and 
helicase-activity deficient mutant, UAP56(D199A): helicase-activity deficient mutant. FLAG-
immunoprecipitation was performed and IP fractions and WCL samples were analysed by 
Western blot using the indicated antibodies. C HeLa cells were transfected with plasmids 
coding for the proteins of interest tagged with GFP β-sheet 10 or 11 (10L-X and 11L-X) as 
indicated, the detector fragment GFP1-9 (GFP β-sheets 1-9) and mCherry as a transfection 
control. Live cell analysis was performed by confocal microscopy. Monomeric MxA(M527D) 
served as a negative control. WCL: whole cell lysate 
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3.5 Kan1 NP(F412A/R416A) loses its binding capacity to MxA as well as UAP56. A HEp-
2 cells were transfected with either FLAG-mCherry or FLAG-UAP56 and Kan1 NP wt or 
different oligomeric Kan1 NP mutants as indicated. FLAG- immunoprecipitation was 
performed. IP fractions and WCL samples were analysed by Western blot using the indicated 
antibodies. B HEp-2-MxA(R640A) cells were transfected with empty vector or plasmids 
coding for either wildtype Kan1 NP or monomeric Kan1 NP mutants as indicated. Cells were 
lysed and an NP- immunoprecipitation was performed. IP fractions and WCL samples were 
analysed using the indicated antibodies. C HeLa cells were transfected with plasmids coding 
for the proteins of interest tagged with GFP β-sheet 10 or 11 (10L-X and 11L-X) as indicated, 
the detector fragment GFP1-9 (GFP β-sheets 1-9) and mCherry as a transfection control. 
Live cell imaging analysis was performed by confocal microscopy. D Vero cells were 
transfected with wildtype Kan1 and the indicated mutants thereof. Cells were lysed and 
samples were dialysed. The samples were run on a gel under non-denaturing conditions. 
Western blot analysis was performed using an α-NP antibody. Molecular weight of NP: 50 
kDa. WCL: whole cell lysate 
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4 An attempt at mapping the interaction domains in MxA and 
UAP56 to each other and to viral NP 
 
4.1 Introduction 
 
The discovery of Mx genes dates back to 1962/64, when Jean Lindenmann found that the 
protein product of one single gene - namely Mx1 - protected inbred mice from a lethal dose 
of IAV92,169. Later on, Mx genes were found to be present in many other species95,167. 
Humans harbor the two closely related genes Mx1 and Mx2, which express the two 
structurally but not functionally very similar proteins MxA and MxB, respectively. The most 
obvious difference is found in their antiviral activity. Whereas MxA has been shown to inhibit 
many RNA- but also some DNA-viruses95,96, MxB has only very recently been shown to 
harbor antiviral potential by antagonizing HIV-1 and other primate lentiviruses113,141 and 
various members of the Herpesviridae family114. Many efforts have been made in the past 
decades to characterize the antiviral activity of MxA and it is now generally thought that the 
viral nucleoprotein (NP) represents its target123. NP is a major component of the viral 
ribonucleoproteins (vRNPs), a structure built of the viral RNA genome segments bound to 
one viral polymerase molecule and covered by multiple copies of NP. These vRNPs are 
located to the core of IAV virions. However, the mode of action of MxA appears to differ 
depending on the virus it acts against and the detailed mechanism remains largely unknown 
for IAV. The MxA-sensitivity of IAVs of different origin varies greatly121-123. Generally, avian 
IAV strains are more sensitive to MxA in contrast to human strains and this sensitivity is 
dependent on the viral NP. MxA sensitivity is reduced or even lost if certain amino acid 
substitutions are introduced in the viral nucleoprotein NP of sensitive strains122,123. Co-
immunoprecipitation (co-IP) experiments revealed the capability of dimeric MxA to bind to 
NPs of various strains115 (see fig. 2.1B, 2.2C). In addition to a viral protein partner it has 
further been shown, that MxA is able to bind to the cellular DEAD-box helicase UAP56 (also 
designated DDX39B)57 (see also fig. 2.1C, 2.3A and B), a nucleo-cytoplasmic shuttling 
protein involved in mRNA biogenesis and nuclear export128,130,176,186. This helicase has 
already been suggested to constitute a pro-viral factor that acts as a chaperone on viral NP29 
but is also required for the anti-IAV activity of MxA135. Here, we demonstrate that UAP56 
binds IAV NP, which provides a structural link in addition to the already established functional 
link of UAP56 and IAV. NP-UAP56 interaction was published concomitantly by Hu et al137. 
Apart from the fact that MxA, NP and UAP56 bind to each other no additional information is 
currently available about the specific regions involved in binding. We thus aimed at mapping 
the regions that mediate MxA-UAP56 and NP-UAP56 interaction by employing deletion 
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mutants of MxA and UAP56. To this end we adapted the tripartite splitGFP assay179 in order 
to visualize the subcellular localization of the interactions between MxA, UAP56 and NP. In 
contrast to the standard splitGFP system the tripartite splitGFP has the advantage of smaller 
tag sizes, higher fluorescence signals and expendability of sample incubation prior to 
microscopic analysis. The tags consist of GFP β-sheets 10 and 11, respectively, which are 
fused to our proteins of interest via an unstructured linker sequence. The complementary 
GFP detector fragment (the remaining β-sheets 1-9), co-expressed from an individual 
plasmid, assembles with the GFP10 and GFP11 tags and complements GFP fluorescence 
whenever the tagged proteins are in sufficiently close proximity. 
To our disappointment we found that UAP56-deletion mutants are not a feasible tool to study 
heterotypic UAP56 interactions, due to the recruitment of endogenous UAP56 to most 
UAP56 deletion mutants. We mapped the domain in UAP56 involved in UAP56 dimerization 
to the region between amino acid residue 227 and 310. Binding studies with MxA deletion 
mutants suggested the involvement of loop L4 in UAP56-binding. However, this could not be 
confirmed, since MxA L4 mutants retained interaction to UAP56. Surprisingly, we were able 
to show MxB-NP and MxB-UAP56 interactions. Taken together, our observation that both 
human Mx proteins bind to NP and UAP56 suggests that MxA and MxB share conserved 
functions that may solely be modulated by their distinct intracellular localization. 
 
4.2 Experimental procedures 
 
4.2.1 Cell lines 
 
All cell lines were cultured in DMEM supplemented with 10% FCS, 1 mg/ml 
Penicillin/Streptomycin and 2 mM GlutaMAXTM (Thermo Fisher Scientific) (complete DMEM) 
at 37°C and 5% CO2. HEp-2 (HeLa-derived human epithelial cells) and HeLa (human 
adenocarcinoma cells) were purchased from ATCC. 
 
4.2.2 Plasmids 
 
As previously described MxA wt cDNA was cloned into pcDNA3.1(+)neo (Invitrogen)158. 
cDNA of GFP β-sheet 10 or 11179 plus and unstructured linker sequence of 32 or 25 amino 
acids (179 supplemental information), respectively was cloned into pcDNA3.1(+)neo. These 
constructs were designed to be suitable as either N- or C-terminal protein tags. For the 
detector fragment consisting of the complementing β-sheets 1-9, cDNA of GFP1-9 was 
cloned into pcDNA3.1(+)neo179. To obtain GFP10- or GFP11-tagged MxA, NP or UAP56 
variants, the respective cDNA was cloned into these vectors using PacI and BamHI. 
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4.2.3 Immunofluorescence assay 
 
Cells were seeded in 24-well format on a cover slide. After transfecting with JetPRIME 
(Polyplus transfection), cells were fixed with 3% paraformaldehyde (PFA) in PBS for 10 min 
at RT and permeabilized with 0.1% or 0.5% Triton-X100 in PBS for 10 min at RT. Staining 
was performed in PBS with 5% goat serum for 1 h at RT (mouse α-MxA (hybridoma ab143, 
1:5). 
 
4.2.4 Tripartite split-GFP complementation assay 
 
HEp-2 or HeLa cells were seeded in an ibidi µ-slide 4-well chamber (Cat. No 80427). Cells 
were transfected with 500 ng DNA (180 ng of each GFP10- or GFP11-tagged construct and 
90 ng GFP1-9) using ViaFectTM (Promega) according to the manufacturer’s instructions. 24 h 
later growth medium was changed to FluoroBrite DMEM medium (Thermo Fisher Scientific) 
+ Hoechst (1:5000) and analysed at a Leica SP5 confocal laser scanning microscope. 
 
4.2.5 Co-immunoprecipitation (co-IP) 
 
HEp-2 cells were transfected with Viafect (Promega) according to the manufacturer’s 
instructions. 24 h post-transfection cells were lysed in 300 µl lysis buffer (20 mM Tris-HCl pH 
7.5, 150 mM NaCl, 5 mM MgCl2, 50 mM NaF, 1 mM Na3VO4, 1% NP-40, 50 mM β-
glycerophosphate, 100 nM iodoacetamide, 1x Roche cOmplete Protease Inhibitor Cocktail) 
in the dark on ice for 30 min. Lysates were homogenized using QiaShredder columns 
(Qiagen). 100 µl of each lysate was incubated with antibody (α-NP (50 µl, HB65, hybridoma, 
in-house) at 4°C over night on a rotating wheel. 15 µl lysate was used for the whole cell 
lysate (WCL) control. 20 µl Dynabeads protein G magnetic beads (Thermo Fisher Scientific) 
per sample were pre-adsorbed over night at 4°C on a rotating wheel using untransfected 
HEp-2 cell lysate. Pre-adsorbed beads were washed once with lysis buffer and incubated 
with the lysates for 1 h at 4°C on a rotating wheel. Beads were washed once with 1 ml 
followed by five times 0.5 ml lysis buffer. Beads were briefly vortexed in between the washing 
steps. Proteins were eluted from the beads with 20 µl 1x Laemmli buffer at 95°C for 10 min. 
15 µl WCL/IP sample was loaded on a 10% SDS-PAGE gel and analysed by Western blot 
(α-NP (rabbit serum, in-house, 1:10’000), α-MxA (ab143, hybridoma, in-house, 1:10)). 
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4.3 Results 
 
4.3.1 Generating MxA deletion mutants to reveal domains necessary for binding to 
UAP56 and NP 
 
The C-terminal stalk of MxA has already been shown to be involved in virus specificity99 and 
we and others99,100,191 also have evidence of the importance of the stalk in the antiviral activity 
of MxA. In order to map the binding sites of MxA to UAP56 and NP we thus decided to focus 
on the C-terminal region of MxA. We thus designed deletion mutants eliminating an 
increasing number of the 5 α-helices, which build up the stalk. The last remaining residues of 
the respective deletions are marked in the schematic representation of MxA in Fig. 4.1A. The 
expression in HEp-2 cells of those deletion mutants was verified by transfection and 
immunofluorescent analysis (Fig. 4.1B). Most of the mutants showed a similar expression 
pattern to wildtype MxA, with the exception of MxA(Δ530-662), which localized to the 
cytoplasm as well as the nucleus, where MxA is normally excluded from. We visualized the 
site of interaction of the MxA deletion mutants with UAP56 by means of the tripartite split-
GFP complementation assay (described in 3.3 and in179). We transfected HEp-2 cells with 
the proteins of interest fused to a splitGFP tag (‘10L-’ or ‘11L-’), the detector fragment GFP1-
9 and mCherry as a transfection control and we observed that interaction to wildtype UAP56 
was lost with MxA(Δ530-662) but not with MxA(Δ575-662) (Fig. 4.1C). Amino acids 530-574 
comprise the whole of loop L4, an unstructured loop which has been implicated in membrane 
binding116 and in the case of mouse Mx1 (a mouse homolog of MxA) in anti-IAV activity101. 
When looking at co-precipitation of the MxA deletion mutants with NP in cells transfected 
with the indicated plasmids, interaction with both MxA(Δ575-662) and MxA(Δ530-662) was 
observed, and this interaction is lost with the MxA(Δ497-662) mutant (Fig. 4.1D). As 
previously described115 (also see chapter 2.1), only interaction of MxA(R640A) but not 
wildtype MxA can normally be visualized by co-IP. Intriguingly, here we report interaction of 
NP with the MxA-deletion mutants, despite the fact that the R640 residue is in the deleted 
part of the molecule. This renders the results challenging to interpret.  
 
4.3.2 Investigating the potential involvement of MxA loop L4 in its capability to bind 
to UAP56 and NP 
 
MxA and MxB are two closely related proteins with a very similar 3D structure. However, 
wildtype MxB does not harbor potent anti-IAV function. In order to clarify the importance of 
loop L4 of MxA for the interaction with UAP56 and NP, we generated MxA-MxB chimeras. 
We exchanged loop L4 in MxA with the according structure in MxB and vice versa. The 
sequence identity of these loops is 32% and the length of the loop in MxB exceeds the one in 
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MxA by two amino acids. We hypothesized that the binding of MxA to UAP56 is abrogated in 
MxA harboring the loop from MxB if L4 is indeed crucial for binding. HEp-2 cells were 
transfected with the splitGFP constituents as indicated in fig. 4.2. To our surprise, UAP56-
binding capacity of MxA(L4-MxB) was not affected in the least compared to wildtype MxA 
(Fig. 4.2A). The complementary chimera MxB(L4-MxA) showed similar binding capacities to 
UAP56 and even MxA(ΔL4), a mutant where L4 was replaced by an unrelated flexible linker 
sequence of the same length, retained its binding capacity to UAP56 (Fig. 4.2A). Therefore it 
is obvious that even if L4 is involved in binding to UAP56 it is clearly not sufficient. Being left 
with no loss of binding phenotype, we investigated the UAP56- and NP-binding capacity of 
wildtype MxB. Intriguingly, binding to UAP56 was indeed observed in a manner similar to 
MxA (Fig. 4.2B) in cells transfected with the indicated plasmids. The interaction was possibly 
slightly more dispersed throughout the cytoplasm. Furthermore, we were actually able to see 
splitGFP complementation of 11L-NP and 10L-MxB in contrast to 11L-NP and 10L-MxA 
expressing cells. The binding to NP could also be confirmed in co-IP experiments (Fig. 3.2B) 
in cells transfected with the indicated plasmids. Since wildtype MxB does not exert anti-IAV 
activity, the interaction to UAP56 and NP was unexpected. These differences in antiviral 
specificity imply, however, that MxA harbors additional features enabling it to counteract IAV 
infection. 
 
4.3.3 Attempts at finding binding sites in UAP56 to MxA and NP 
 
We further wanted to narrow down the region(s) in UAP56 necessary for the binding to MxA 
and NP. We aimed at addressing this issue with deletion mutants as well. UAP56 is a 
crescent shaped protein with two globular domains connected by a flexible linker (Fig. 4.3A). 
We chose a selection of N- and C-terminal deletion mutants according to Thomas et al.128 
(Fig. 4.3B). We first subjected the C-terminal deletion mutants to split-GFP complementation 
analysis in order to monitor the interactions with MxA (Fig. 4.3C) and NP (Fig. 4.3D). The 
perinuclear GFP signal seen in MxA- transfected cells remained unchanged independent of 
the length of the deletion in UAP56 (Fig. 4.3C). Also, nuclear localization of UAP56-NP 
interaction was clearly visible using the same UAP56-deletion mutants (Fig. 4.3D). When N-
terminal UAP56 deletion mutants were tested in conjunction with NP and MxA a loss of 
interaction was not observed either (data not shown). We hypothesized that this phenotype is 
resulting from the interaction of the UAP56 deletion mutants with endogenous UAP56 so that 
MxA and NP are able to bind to the mutants indirectly via wildtype UAP56. To validate this 
hypothesis we examined the interaction potential of the deletion mutants with wildtype 
UAP56 (Fig. 4.4). Cells were transfected with 11L-UAP56wt and various 10L-UAP56 deletion 
mutants and we saw that complex formation was unaffected for some but not all mutant 
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UAP56 proteins (Fig. 4.4A). Interaction was only lost with UAP56(Δ201-428) (Fig. 4.4A, 
schematic representation shown in fig. 4.4B). In conclusion, we narrowed the dimerization 
domain down to amino acids 227 to 310 of UAP56 (highlighted in orange in fig. 4.4B). 
Furthermore, the observed loss of UAP56 dimerization but not binding to MxA and NP in N-
terminal deletion mutants (compare fig. 4.4A with 4.3C) proposes the N-terminus to being 
part of the MxA- and NP-binding domain. 
 
4.4 Discussion 
 
In this chapter we aimed at mapping the interaction domains of MxA and the helicase UAP56 
to each other as well as to viral NP. We made use of the tripartite splitGFP system described 
in Cabantous et al179. In contrast to the standard splitGFP complementation assay, where the 
two halves of GFP are used as protein tags, the improved tripartite splitGFP system utilizes 
only the very last C-terminal β-sheets of GFP as tags for the proteins of interest. This is an 
easy approach to quickly uncover regions involved in binding of two proteins. We adopted 
this system to study MxA-UAP56 interactions as well as interactions with NP. We thus 
generated various deletion mutants of MxA and UAP56. MxA truncation mutants first 
suggested loop L4 to be part of the UAP56-interaction domain. Further experiments with 
MxA L4 mutants, however, could not strengthen these data. Unexpectedly, the tripartite 
splitGFP system did not appear to be a suitable experimental approach to map UAP56 
interaction domains. Sustained binding of endogenous UAP56 with the UAP56 deletion 
mutants interfered with the characterization of UAP56-MxA and UAP56-NP interactions. 
Nevertheless, we were able to narrow down the region involved in UAP56 dimerization to 
residues 227-310. 
 
The inability to detect NP-MxA interaction with this approach was unexpected (data not 
shown), since robust interaction can be observed in NP-pulldown experiments (chapter 2 and 
3 and115). However, tagging of proteins by attaching additional amino acids can interfere with 
the ability of those proteins to interact with other partners due to steric hindrance. In this work 
we used only N-terminally tagged MxA and NP proteins, based on a number of reasons. The 
N-terminus of MxA comprises the G-domain170 and it is generally believed that the G-domain 
confers structural rearrangements to the stalk upon GTP hydrolysis98,100, thus we believe the 
stalk offers a more suitable structure for protein binding. Also, the arginine residue at position 
640 (R640), which is crucial for dimerization, is located at the C-terminal one part of the 
bundle-signaling element (BSE) of MxA170. MxA in some of our co-IP assays (eg. Fig. 3.3C) 
harbors an N-terminal FLAG-tag and that did not interfere with NP-binding or activity. The 
crystal structure of trimeric NP reveals that the N-terminus is not involved in 
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oligomerization50,51. It is situated at the outermost part of trimeric NP where it forms a 
protrusion. This makes the N-terminus a suitable target for the addition of another peptide as 
a tag. Not much is known about UAP56 and its dimeric structure so we tested both N- and C-
terminal tagging. In the case of UAP56, it does not seem to matter if the tag is at the N- or C-
terminus, complex formation of tagged UAP56 with MxA and NP was not affected (data not 
shown). In contrast to MxA-interaction, NP harboring an N-terminal splitGFP-tag still retains 
the capacity to interact with UAP56. We thus hypothesized that in the trimeric MxA-UAP56-
NP complex, UAP56 is the ‘linker’ protein between MxA and NP, so that MxA and NP are too 
far apart from each other to allow splitGFP complementation. Extending the 30 amino acid 
linker sequence might possibly resolve this issue. On the other hand this could then also 
increase the rate of false-positives, due to random complementation. 
 
Starting off with mapping the UAP56-interaction domain of MxA by consecutively larger C-
terminal deletions, our results suggested loop L4 to be the potential region of interaction (Fig. 
4.1C). Loop L4 has already been shown to be a determinant of antiviral activity of MxA 
against IAV and THOV100,153. We speculated that the antiviral activity of MxA is dependent on 
UAP56 und is thus indirectly mediated via the ability of MxA to bind to UAP56 via loop L4. 
However, the more elaborate MxA-MxB chimeric mutants showed sustained binding 
capabilities of all the tested chimera (Fig. 4.2). Swapping of whole domains between MxA 
and MxB did not result in loss of UAP56-binding and it has also been shown that swapping 
the loops between Mx proteins of different species is single amino acid mutations in L4, 
which have been shown to alter the antiviral activity against THOV and IAV99,191, would be 
the next mutants to investigate. On top of that we uncovered the ability of MxB to interact 
with UAP56 in the cytoplasm. This was quite surprising, since MxB is lacking anti-IAV 
activity. On the other hand, MxA and MxB are very similar, thus the potential of MxB to 
interact with UAP56 might seem obvious. Nevertheless, binding is certainly not sufficient to 
exert anti-IAV activity and MxB might lack other characteristics, which are present in MxA, 
such as possibly the slight differences in tertiary structures or sub-cellular localization, which 
makes it unsuitable to inhibit IAV replication. We have evidence, though, that nuclear MxB is 
potent at restricting IAV replication (see chapter 2), which might account for the UAP56- and 
NP-binding capacity of MxB (Fig. 4.2B and fig. 2.4). It is also in line with reports, show 
binding of Mx1, a mouse homolog of MxA localized to the nucleus, to UAP5657 and NP151. 
 
It is very intriguing that interaction of wildtype MxA cannot be visualized with co-IP 
experiments. The dimeric MxA(R640A) co-precipitates with NP (see chapter 3). However, 
this residue is deleted in all the MxA C-terminal deletion mutants used in the NP-pulldown in 
fig. 4.1D. We were thus lacking a suitable positive control. Nevertheless, we observed NP-
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binding with MxA(Δ575-662) and MxA(Δ530-662) (Fig. 4.1D), which suggested the 
involvement of the α3-helix in NP binding, either directly or indirectly via changes in the 
tertiary structure of MxA. 
So far, we could show that interaction of MxA with NP is highly dependent on the dimeric 
state of MxA (Fig. 3.3C and D). We have no data on folding and homotypic interactions of the 
MxA deletion mutants but it might well be that they assemble in dimers and thus form a 
complex with NP. Alternatively, the C-terminal deletions in MxA may result in an increased 
accessibility of the NP- and/or UAP56-binding site which may result in stable NP co-
precipitation. We hypothesize that wildtype MxA, on the contrary, needs to undergo 
conformational changes upon NP-binding and possibly GTP hydrolysis, which subsequently 
releases NP from MxA and leads to a highly transient binding phenotype. Co-IP experiments 
with a cross linker to stabilize wildtype MxA-NP interaction might is a means to address this 
issue. 
 
To circumvent the problem with the interference of endogenous UAP56 with our binding 
assay, cell lines depleted or at least with reduced levels of UAP56 are needed. We suspect, 
however, that the closely related and partially redundant helicase URH49189 would then take 
over some of the functions of UAP56 and its expression might be upregulated. Additionally, 
due to the ability of URH49 to bind to MxA57 and UAP56192, UAP56 and URH49 would need 
to be downregulated simultaneously. This, however, greatly reduces cell viability (data not 
shown), which makes those cells unsuitable for splitGFP experiments. Instead of performing 
mapping studies of UAP56 deletion mutants with MxA and NP we were able to uncover the 
dimerization site of UAP56, which, according to our data, involves residues 227-310, the 
flexible linker between the N- and C-terminal globular domains. This is in partial accordance 
with Zhao et al193, who proposed the N-terminus (via salt bridge formation between residues 
R123 and D62, E134 and K138 and K156 and E55 of the first and the second UAP56 
molecule, respectively) or amino acids 198 - 244 to harbor a dimerization domain according 
to UAP56’s crystal structure. They state that the likelihood of the second dimer interface 
being the biologically relevant is lower than the first, because dimer formation in this fashion 
is “rarely observed in biological systems”. We, on the other hand, have experimental 
evidence that strongly suggests the second interface to be the relevant dimer interface. 
UAP56 lost dimerization capability, when residues 201-428 of UAP56 were deleted (Fig. 4.4) 
but this mutant retained its capability to interact with MxA and NP (data not shown). Taken 
together, these data suggest the C-terminal residues 201-428 to be dispensable for NP and 
MxA binding. 
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Another issue is the observed difference in splitGFP complementation signal intensity 
between different samples. These differences are challenging to interpret and we question 
the biological relevancy. It is known that due to the irreversibility of GFP complementation, 
transient or weak interactions are stabilized179,194. This stabilization could explain differences 
in signal intensities. We do not know the extent of this stabilizing feature in our particular set 
of experiments. But differences in binding strengths between mutants with reduced 
interaction capacities and mutants still harboring the full binding potential might well be 
reflected in differences in GFP signal intensities. Thus, the loss of binding mutants we found 
have most likely completely lost their binding capacity and such mutants are the only feasible 
candidates for splitGFP experiments.  
Taken together, the tripartite splitGFP assay is an easy-to-use system to study protein-
protein interactions. It was not suitable, however, for our experimental setup due to complex 
interactions involving more than one interface. This means first of all oligomerization of MxA, 
NP and UAP56 and in addition to this, the interaction of those oligomers with each other. We 
were thus not able to conclusively map binding domains of MxA and UAP56. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
D 
IP α-NP 
WCL 
MxA 
Kan1 NP - + + + + 
wt wt Δ575 Δ530 Δ497 
α-MxA 
α-MxA 
α-NP 
α-NP 
Fig. 4.1 
A 
MxA wt MxA Δ575 MxA Δ530 MxA Δ497 MxA M527D MxA Δ363 
α-MxA 
B 
10
L-
M
xA
(Δ
53
0-
66
2)
 
- 
11
L-
U
AP
56
 w
t 
10
L-
M
xA
(∆
36
3-
66
2)
 
- 
11
L-
U
AP
56
 w
t 
10
L-
M
xA
 w
t 
- 
11
L-
U
AP
56
 w
t 
10
L-
M
xA
(∆
57
5-
66
2)
 
- 
11
L-
U
AP
56
 w
t 
Hoechst mCherry GFP complement. Merge C 
71 
An attempt at mapping the interaction domains in 
MxA and UAP56 to each other and to viral NP 
72 
 
4.1 Binding capacities of C-terminal truncations mutants of MxA to NP and UAP56. A 
Schematic representation of the 3D structure of MxA (left) and a linear representation (right) 
with the first residue, which is deleted in the corresponding mutant indicated by a red arrow. 
B HEp-2 cells were transfected with plasmids coding for wildtype MxA or the indicated MxA 
mutants. Cells were fixed, stained as indicated and analysed by confocal microscopy. C 
HEp-2 cells were transfected with plasmids coding for the proteins of interest tagged with 
GFP β-sheet 10 or 11 (10L-X and 11L-X) as indicated, the detector fragment GFP1-9 (GFP 
β-sheets 1-9) and mCherry as a transfection control. Live cell imaging was performed at a 
confocal microscope. D HEp-2 cells were transfected with plasmids encoding wildtype MxA 
or MxA deletion mutants as indicated together with a Kan1 NP expression plasmid. Cells 
were lysed and an NP- immunoprecipitation was performed. IP fractions and WCL samples 
were analysed by Western blot using the indicated antibodies. WCL: whole cell lysate 
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4.2 Testing loop L4 of MxA for its potential as a prerequisite for UAP56 binding. A and 
B HEp-2 cells were transfected with plasmids coding for the proteins of interest tagged with 
GFP β-sheet 10 or 11 (10L-X and 11L-X) as indicated, the detector fragment GFP1-9 (GFP 
β-sheets 1-9) and mCherry as a transfection control. Cells were analysed by confocal 
microscopy. MxAL4-MxB: wildtype MxA harbouring the corresponding loop from MxB instead 
of loop L4, MxBL4-MxA: wildtype MxB harbouring loop L4 from MxA instead of its 
corresponding loop, MxAΔL4: wildtype MxA where loop L4 was exchanged with an 
unstructured linker sequence. 
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4.3 UAP56 deletion mutants are not feasible to for interaction studies. A Crystal 
structure according to Shi et al., 2004 visualized with PyMOL (RCSB protein data bank ID: 
1xti). Mutations affecting the helicase (D199A) and ATPase/helicase (K95A) functions are 
highlighted in yellow. B Schematic representation of the N- and C-terminal UAP56 deletion 
mutants based on Thomas et al. The arrow indicates the flexible linker between the N- and 
C-terminal globular tertiary structures. C and D Interaction capacities of wildtype MxA (C) or 
wildtype Kan1 NP (D) with wildtype UAP56 or C-terminal deletion mutants thereof. HEp-2 
cells were transfected with plasmids coding for the proteins of interest tagged with GFP β-
sheet 10 or 11 (10L-X and 11L-X) as indicated, the detector fragment GFP1-9 (GFP β-sheets 
1-9) and mCherry as a transfection control. Live cell imaging was performed on a confocal 
microscope. 
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4.4 Mapping the dimerization domain in UAP56 to amino acid residues 227-310. A HEp-
2 cells HeLa cells were transfected with plasmids coding for the proteins of interest tagged 
with GFP β-sheet 10 or 11 (10L-X and 11L-X) as indicated, the detector fragment GFP1-9 
(GFP β-sheets 1-9) and mCherry as a transfection control. Live cell imaging was performed 
on a confocal microscope. B Schematic representation of the different UAP56 deletion 
mutants and their oligomerization capacity. Colours indicate retained ability to form oligomers 
(green) or a loss thereof (red). The putative dimerization domain is highlighted in orange. 
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5 General discussion 
 
In response to virus infection the innate immune system induces the production of many 
proteins with potent antiviral functions. Mx proteins represent a small group of such effector 
proteins and are present in a variety of species. Almost all mammal genomes harbor two 
genes: MX1 and MX295. Despite their remarkable structural resemblance, the protein 
products of those two genes nevertheless harbor some distinct features. Mouse Mx1 and its 
human homolog MxA restrict a panel of viruses, mainly RNA viruses (reviewed in95), among 
them IAV, but MxA has also been shown to inhibit some DNA viruses111,195. They localize to 
different subcellular compartments and also inhibit IAV at different stages of its replication 
cycle. The viral targets are known for many viruses to be nucleoproteins, ribonucleoprotein 
complexes or nucleocapsids (reviewed in95). Despite extensive investigations of Mx1 and 
MxA antiviral functions over the past decades the molecular mechanism of action is still 
unresolved. Mouse Mx2 and human MxB do not show potent anti-IAV activity and were only 
shown to inhibit vesicular stomatitis virus (VSV)149 and Hantaan virus148 or human 
immunodeficiency virus type 1 (HIV-1)113,157,196, other primate lentiviruses113 and human 
herpesviruses114, respectively. 
The cellular RNA-helicase UAP56 has been shown to play a role for both IAV infection133 and 
the antiviral activity of MxA135. This helicase was also found to bind to MxA and Mx157 as well 
as viral NP136 supposedly exerting a chaperone function. The research topics of this thesis 
were therefore the following: (i) investigation of nuclear MxB on its anti-IAV activity, (ii) 
characterization of the proposed MxA-NP-UAP56 trimeric complex and (ii) mapping of 
binding sites in MxA and UAP56 to each other as well as NP. 
 
In the first part of this work (chapter 2) we showed that nuclear MxB potently inhibits IAV 
replication at a step prior to or at the level of primary transcription. Work presented in the 
second manuscript (chapter 3) aimed at shedding more light onto the antiviral mechanism of 
MxA and its effect on the NP-UAP56 complex. We observed no interference of MxA with the 
translocation of newly synthesized viral NP to the nucleus or with the binding of NP’s 
chaperone UAP56 to NP. Binding strength of a variety of NPs turned out not to correlate with 
their respective MxA sensitivity. In addition, the binding capacity of MxA to NP is independent 
of a functioning G-domain and thus not sufficient to exert its antiviral potential. We further 
found NP residues F412 and R416, which are involved in NP oligomerization, to be crucial 
for the binding of NP to MxA and UAP56. In the last part (chapter 4) we aimed at mapping 
the binding sites of MxA and UAP56 to each other and viral NP with the tripartite splitGFP 
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assay. However, we were only successful to narrow down the region in UAP56, which is 
involved in its oligomerization. 
 
5.1 The antiviral mechanism of MxA: an initial model 
 
After viral entry, primary transcription and export of the viral mRNA to the cytoplasm 
translation of viral proteins takes place. NP is one of the viral proteins, which are 
subsequently needed in the nucleus for viral replication, since it must be added co-
transcriptionally to the growing RNA chain52-54. It is an RNA-binding protein without sequence 
requirements35 and has been shown to interact with the cellular RNA-helicase UAP56 most 
likely already during translation29,57. This interaction is thought to exert a chaperone function 
on NP and ensure its proper delivery to the vRNA in the nucleus. We further speculated that 
the chaperone function of UAP56 is crucial to prevent NP from unspecifically binding cellular 
RNA, since its affinity for RNA is relatively high34. Our initial model for the mechanism of 
action of MxA (graphically summarized in fig. 6.1) described a scenario in which dimeric MxA 
would either (i) inhibit NP from reaching the nucleus or (ii) bind to NP-UAP56 hetero-
oligomers and separate the chaperone from NP. For the latter concept the conserved G-
domain in MxA can be neatly explained by the need for structural rearrangements through 
GTP hydrolysis to achieve a ‘power-stroke’ similar to the one described for dynamin197,198. In 
both of those scenarios NP would eventually be unavailable for viral replication: in the first 
case because of the inability to reach its intended destination and in the second scenario 
because of consequential binding to cellular RNA and thus unavailability for vRNA 
encapsidation. Higher order oligomers of MxA would represent a pre-active storage form of 
MxA. 
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Fig. 6.1. Initial model for the antiviral action of MxA. The model describes two potential mechanism 
of the anti-IAV activity of MxA: either (i) transport of the UAP56-NP complex to the nucleus is inhibited 
or (ii) MxA separates NP from its chaperone UAP56 resulting in binding of NP to cellular RNA. 
 
5.2 Adjustments to the model 
 
We showed that MxA does not inhibit translocation of NP from the cytoplasm to the nucleus 
by a subcellular fractionation approach. Furthermore, NP-UAP56 interaction is undisturbed in 
the presence of MxA. This suggests that the NP-UAP56 complex does reach the site of viral 
replication. All the three proteins previously interact with each other in the cytoplasm forming 
a trimeric complex. We have strong evidence that the site of interaction is the cytoplasm 
since MxA has never been shown to localize to the nucleus. Furthermore, nuclear forms of 
Mx (Mx1 and TMxA) proteins interfere with the function of PB2151,199, which is not seen for 
MxA115. These data thus point towards a more indirect mechanism of MxA to inhibit 
replication probably through post-translationally modifying NP or UAP56 or both. 
Alternatively, MxA might induce a transient separation of UAP56 and NP resulting in the 
binding of NP to cellular RNA. 
Furthermore, we cannot exclude the involvement of an additional cellular factor. For human 
cytomegalovirus it has been shown for example, that the viral regulatory protein pUL69 
interacts with UAP56 as well as the cellular protein arginine methyl transferase PRMT6200. 
This interaction resulted in methylation of pUL69. Even though UAP56 and PRMT6 were 
shown to not directly interact200, we could envision a similar mechanism for influenza virus 
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where MxA recruits enzymes that add post-translational modifications (i.e. phosphorylation41) 
or on the contrary remove modifications at defined residues impairing the function of NP or 
UAP56. It has been shown for instance that acetylation of certain residues in NP is crucial to 
support viral growth49. Phosphorylation at specific residues at the very N-terminus of NP 
have been shown to impair the binding capacity to importins and thus the import of NP into 
the nucleus leading to cytoplasmic accumulation of NP201. If other residues are 
phosphorylated, NP loses its ability to oligomerize and vRNP generation is thus impaired. 
The modification(s) of NP and/or UAP56, which are presumably added in the presence of 
MxA, have thus to be added at specific residues to lead to the desired effect of viral 
replication inhibition. 
All in all, we propose that the re-localization of the UAP56-NP complex to the nucleus is not 
perturbed. However, dimeric MxA is likely to destroy the integrity of this complex through the 
recruitment of a yet unknown factor, which adds post-translational modifications to UAP56, 
NP or both. These modifications then interfere with the function(s) of UAP56 and/or NP. This 
is summarized in fig. 6.2. The GTPase activity of MxA could potentially be needed for the 
recruitment of this additional factor. 
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Fig. 6.2. Adjusted model for the antiviral action of MxA. MxA could potentially (with the help of 
another factor) be involved in the addition of post-translational modifications to the UAP56-NP 
complex. This renders the complex non-functional. 
 
5.3 Primary transcription: inhibition or not? 
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Intriguingly, we observed inhibition of viral primary transcription in cells expressing wildtype 
MxA. Although it has been shown that primary transcription is not affected by MxA115,117 
others have seen that viral transcripts are actually not generated178. The assays used in 
those studies are basically the same, yet the chosen cell lines are different. It is rather 
doubtful, however, that this explains the seemingly contradictory results. In the case of 
Thogoto virus, an RNA virus with a segmented ssRNA genome of negative polarity like IAV, 
MxA interferes with the import of nucleocapsids, which results in the inhibition of primary 
transcription175. UAP56 is thought to function as a chaperone of newly synthesized viral NP 
and we have previously shown that UAP56 further binds to MxA57. UAP56-NP binding, and 
likely also UAP56-MxA binding, occurs at the step of NP mRNA translation, thus MxA seems 
to be capable of inhibiting IAV replication at two steps affecting both primary transcription 
and viral genome replication as previously suggested122,177. We could imagine that this is a 
type of safeguard mechanism of the cell, ensuring that progeny virus formation is indeed 
inhibited even if MxA fails to inhibit primary transcription of the incoming virus particles. 
 
5.4 Mx proteins and their ability to bind to IAV NP 
 
MxA-sensitivity of a given viral strain is defined through its NP and human IAV strains have 
evolved their NP to partially escape MxA-restriction. Mutations in only a few specific residues 
have been shown to greatly affect virus sensitivity to MxA122,123. The lack of apparent 
correlation between virus sensitivity to MxA and NP-MxA binding strength thus came as a 
surprise to us. We speculated that MxA-sensitivity is rather indirectly determined through 
UAP56-binding capacities. These UAP56 knock-down data did not clarify the situation, 
however, since reduced UAP56 levels also negatively affected general protein levels. This is 
not unexpected, since UAP56 is involved in mRNA export130,131,181,189,193 and reduced export 
capacity results in decreased protein production. Also the closely related and partially 
redundant helicase URH49189 is likely not able to take over all of the function of UAP56. We 
were thus unable to resolve the determinants for NP-MxA binding differences. Nevertheless, 
a common feature to Mx proteins seems to be the oligomeric state in which they bind to NP. 
The dimeric mutant MxA(R640A), as opposed to tetrameric wildtype MxA, is forming stable 
complexes with NP as seen in co-IP experiments. There is a tendency of NPs of MxA-
resistant IAV strains to bind stronger to MxA than NPs of sensitive strains. This strong 
binding possibly leads to sequestration of MxA or even inhibition of its “catalytic” activity, 
allowing the remaining NP to travel safely to the nucleus.  
Wildtype MxB, which has been shown to be dimeric141, also co-precipitated with NP. We 
further observed binding of TMxB to NP, therefore assuming that TMxB is dimeric as well. 
When looking at mouse Mx1 it has been shown to bind to IAV NP in vRNPs as well as to NP 
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only151. Analysis of the oligomeric state of Mx1 would thus be of high interest and we would 
predict it to be dimeric. 
 
5.5 Is there a common antiviral mechanism for all Mx proteins? 
 
Prerequisite for a common mechanism is that Mx proteins have the capacity to bind many 
different viral structures. Interestingly, so far for none of the target viruses, a binding site on 
MxA has been determined. It is clear that the L4 loop plays a role for recognizing viral 
proteins in particular NPs from orthomyxoviruses99-101. However, we observed that loop L4 
alone is not sufficient for binding and other (carboxy terminal) regions are required. Possibly, 
Mx proteins recognize a common site on viral proteins that are required for attachment to 
microtubular intracellular transport mechanisms. Incoming viruses need to transport their 
capsids vRNPs via microtubular transport processes to their specific site of replication. Mx 
proteins may interfere with this transport processes. Canine Mx1 has been shown to 
positively affect the transport of molecules to the apical membrane202. VPS1, an Mx-like 
protein in yeast, was shown to play a crucial role in sorting of soluble vacuolar proteins and 
the correct organization of intracellular membranes203. 
 
A common antiviral mechanism would further suggest that Mx proteins, localizing to the 
same subcellular compartment, should exert similar antiviral activities especially considering 
the step targeted in the viral life cycle. IAV is thought to be inhibited at two steps of its viral 
replication cycle: before primary transcription at the step of nuclear translocation of the 
vRNPs and at a later step after translation by targeting the UAP56-NP complex. MxB was 
thought not to harbor any anti-IAV function, but we could show that re-located nuclear TMxB 
potently inhibited IAV replication at the step of primary transcription. This goes in line with 
data showing that other nuclear Mx proteins, namely mouse Mx1117 and nuclear MxA 
(TMxA)173, abrogate primary transcription as well. Interestingly, in our plaque assay as well 
as mini replicon assays we observed a slight, but constant decrease of viral replication in the 
presence of MxB. MxA and MxB do not localize to the same subcellular compartments. MxA 
as well as a fraction of MxB are present in the cytoplasm, however, MxA has been shown to 
associate with the smooth ER102,140. MxB also associates with the cytoplasmic face of the 
nuclear envelope. We speculate that the aforementioned weak anti-IAV activity of MxB could 
be explained by a small fraction of MxB, localizing to the same compartment as MxA. In 
order to test this hypothesis, MxB re-localization to the same smooth ER sub-compartment 
as MxA would be needed. The sequence in MxA responsible for smooth ER localization 
remains elusive102 though. So far we were not able to confirm this hypothesis with another 
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approach using a cytoplasmic Mx1 mutant either, due to the fact that this mutation abrogated 
the antiviral potential of Mx1 in general. 
More evidence either for or against a common mechanism is needed. The naturally occurring 
short isoform of MxB142, lacking the N-terminal 25 amino acids, loses it perinuclear 
localization and is only found in the cytoplasm. The pattern of expression is reminiscent of 
the expression pattern of MxA. This MxB(Δ1-25) mutant might therefore localize to the same 
subcellular compartment as MxA and possibly restrict IAV replication.  
 
5.6 Outlook 
 
Mx proteins are very similar in structure yet they seem quite different in their antiviral 
activities. Various pieces of evidence now point towards a general mechanism of action. 
However, there are still a few big gaps in our knowledge about Mx proteins for instance 
about the function of the GTPase activity or how exactly Mx proteins inhibit viruses in the 
cytoplasmic and nuclear compartments. The long held fascination for Mx proteins is far from 
ceasing and there are still many mysteries to be unraveled. 
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